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ABSTRACT 
METHODS TO INCREASE TEMOZOLOMIDE SENSITIVITY IN GLIOBLASTOMA 
MULTIFORME: MANIPULATING PARP-1 AND MGMT 
 
By 
Vanessa Loraine Thibado 
 
Glioblastoma multiforme (GBM) is the most malignant and frequent primary 
brain tumor in adults. These tumors expand quickly and tend to recur despite surgery, 
radiation, and chemotherapy treatments. Alkylating agents, such as Temozolomide 
(TMZ), are currently the chemotherapy drugs of choice. Resistance to alkylating agents 
via direct DNA repair by O
6
-methylguanine methyltransferase (MGMT) has arisen as a 
significant barrier to effective treatment. Poly(ADP-ribose) polymerase-1 (PARP-1) is 
activated by binding to DNA breaks, and has functions related to the DNA repair done by 
MGMT. Therefore, inhibition of PARP-1 has been associated with increased sensitivity 
to DNA-alkylating agents. The goal of this research was to characterize several PARP 
and MGMT manipulating treatments in four glioblastoma cell lines. Clinically relevant 
silencing methods were investigated and dose response assays were used for determining 
the efficacy of treatments. Research studies such as this are important in the identification 
of therapies that can overcome drug resistance, lessen cytotoxic side effects, and 
ultimately improve the prognosis of glioblastoma patients. 
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INTRODUCTION 
 
 
 
 
  Malignant tumors derived from glial cells, which form the supportive tissue of 
the brain, are the most common type of central nervous system tumor (Schor, 2009). 
Among these, glioblastoma multiforme (GBM) is the most aggressive and frequent 
primary brain tumor in adults. According to 2008 statistics from the American Cancer 
Society, glial neoplasms represent 0.5-1% of the overall cancer incidence in Western 
countries. The standard of care for newly diagnosed GBM includes surgery, followed by 
concomitant external beam radiation therapy with temozolomide (TMZ) (Yip et al., 
2009).  Unfortunately, the median survival for these GBM patients remains 
approximately one year despite the recent addition of TMZ to the standard of care 
(Johannessen et al., 2008).  These tumors present a number of defenses that make them 
therapeutically challenging, most notably blood-brain barrier penetration and multiple 
mechanisms for pharmacoresistance. Additionally, the rapid recurrence of GBM remains 
a major obstacle to successful treatment.  
  The normal effects of DNA repair are an important issue when considering 
treatment of pharmacoresistant glioblastoma. A well known class of chemotherapy drugs, 
such as TMZ, act by adding a methyl group to the DNA which causes base pair mis-
match and activates futile repair mechanisms, ultimately resulting in cell death. 
Resistance to this class of chemotherapeutic drugs occurs when tumor cells possess an 
enzyme called O
6
-methylguanine methyltransferase (MGMT), capable of reversing 
chemotherapy-induced events that would otherwise lead to cell death in treated cells 
(Hegi et al., 2008). MGMT expression varies between individuals and clinical outcome 
 
 
has been shown to correlate with expression levels in patients, with worse prognoses for 
patients with higher MGMT levels (Hegi et al., 2005). Thus far, there has been limited 
success with combination therapies that target the MGMT enzyme, due in part to serious 
toxic side effects (Liu and Gerson, 2006). However, targeting alternative pathways offers 
new directions to try to overcome pharmacoresistance. 
When approaching adjuvant or concomitant chemotherapy options it is 
evolutionarily useful to target multiple pathways. In this way, it should take the cancer 
cells longer to evolve chemoresistant mechanisms. This reasoning has been applied to 
findings using BCNU, a chemotherapy agent that depletes MGMT, but has serious issues 
with acquired resistance (Schor, 2009). In resistant tumors, activation of the Fanconi 
anemia pathway for DNA damage repair was observed (Chen et al., 2007). PARP-1 has 
been implicated in this pathway, in addition to several other DNA damage repair 
pathways important in mediating chemoresistance in glioblastoma (Curtin, 2007). 
Moreover, the identification of MGMT promoter methylation as a predictive prognostic 
indicator of benefit from TMZ therapy could also have prognostic value for therapeutics 
targeting pathways that increase the antitumor efficacy of TMZ (Hegi et al., 2008). 
The research presented in this thesis investigates clinically relevant silencing 
methods and the effects of temozolomide, PARP-inhibition, and MGMT and PARP-1 
siRNA treatment on four GBM cell lines. Inhibition of PARP-1 has been associated with 
increased sensitivity to chemotherapy agents like TMZ, the effect of PARP-1 inhibition 
and PARP-1 siRNA treatment was explored. Thus, combination studies of MGMT and 
PARP-1 manipulation were done to compare the most effective method for increasing the 
sensitivity to TMZ in the GBM cell lines. 
 
 
CHAPTER ONE: POLY (ADP-RIBOSE) POLYMERASE-1 
 
 
 
 
Poly (ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme that performs key 
roles in a wide variety of cellular processes. PARP-1 synthesizes poly(ADP-ribose) 
(PAR) from its substrate, nicotinamide adenine dinucleotide (NAD+), which it uses for 
covalent post-transcriptional modification of nuclear proteins (D'Amours et al., 1999). 
PARP-1 proteins are found exclusively in the nucleus, as shown by conventional 
fluorescence microscopy; however, rather than homogenous distribution within the 
nucleus, PARP-1 associates with specific structures (Concha et al., 1989). The 
poly(ADP-ribosyl)ation (PARylation) reaction has been implicated in diverse signaling 
and regulation pathways: chromatin modulation, transcriptional regulation, mitotic 
apparatus formation, cell death pathways and DNA damage detection and repair (Kraus, 
2008). These cellular and molecular roles are necessary for multiple physiologic 
processes including overall genome maintenance, neuronal function, aging, inflammatory 
responses and carcinogenesis, among others (Kim et al., 2005). Some of the roles that 
PARP-1 plays have recently been targeted for drug development to be utilized in stroke 
and cancer therapies(Ratnam and Low, 2007). 
 
STRUCTURE AND FUNCTION 
The ADPRT gene is located on the long arm of chromosome one and encodes the 
113 kDa PARP-1 protein. There are three major domains that contribute to the 
multifunctional enzymatic abilities of PARP-1. The N-terminal DNA binding domain 
(DBD) contains two zinc fingers, a nuclear localization signal, and a third zinc binding 
 
 
domain. The zinc fingers recognize and mediate binding to altered DNA structures such 
as single and double strand breaks, cruciforms, crossovers and nucleosomes, rather than 
specific DNA sequences (Kim et al., 2005). Overall the DBD contains a high proportion 
of basic residues which probably help PARP-1 interact with DNA via charge attraction. 
A central automodification domain (CAD) contains a BRCT domain with a leucine 
zipper.  Primary structure analysis reveals 15 conserved glutamate residues, which serve 
as the target in PARP-1 automodification via PARylation (Kawaichi et al., 1981). The 
BRCT motif is important in protein-protein interactions, allowing interacting proteins to 
establish strong and specific associations (D'Amours et al., 1999). The catalytic domain is 
located at the C-terminal and contains the NAD+ binding domain and the “PARP 
signature”. The basal activity of PARP-1 is low until DNA binding through the DBD 
domain and protein-protein interactions mediated via the CAD allosterically activate the 
catalytic domain of PARP-1, which is responsible for PARylation (Kraus, 2008). These 
structural features contribute to the myriad functions PARP-1 is capable of within the 
nucleus. 
 
BIOCHEMISTRY AND REGULATION OF PAR 
Called the “third type of nucleic acid” by some PARP-enthusiasts, PAR was 
discovered in 1963 (Chambon et al., 1963). PAR is a polymer of repeating ADP-ribose 
units with a heterogeneous nature that suggests different forms of PAR could have 
distinct functions within the cell (D'Amours et al., 1999). Each PAR residue has chemical 
properties that allow specific interactions: adenine can base stack and hydrogen bond, 
and the two phosphate groups carry negative charges (Kim et al., 2005). In addition, the 
 
 
site specific covalent addition of a large, negatively charged PAR polymer on proteins 
could have profound effects on the activity of acceptor proteins (D'Amours et al., 1999). 
This is especially true for proteins that interact with DNA, which accounts for many of 
PARP-1‟s functions within the cell. Anabolic PARylation reactions are under the control 
of PARP-1; however, the catabolism of PAR requires additional enzymes, poly(ADP-
ribose) glycohydrolase (PARG) and an ADP-ribosyl protein lyase, which work together 
to hydrolyze the glycosidic linkages between ADP-ribose units to generate free ADP-
ribose (Kim et al., 2005). Thus, PAR polymers have a transient nature in cells, controlled 
mainly by the opposing actions of PARP-1 and PARG and the regulatory mechanisms 
governing these two enzymes.  
PARP-1 has a low basal enzymatic activity, but can be potently activated by 
interacting with DNA and protein binding partners. PARG is also regulated in more than 
one way. A single gene encodes multiple PARG proteins, produced by alternative mRNA 
splicing (Davidovic et al., 2001). One isoform contains a nuclear localization signal, and 
thus resides in the nucleus. However, the other isoform remains in the cytoplasm because 
it lacks a nuclear localization signal (Meyer-Ficca et al., 2004). There has been little 
research to understand why a significant portion of PARG enzyme is located in the 
cytoplasm when the PARylation reactions that it regulates occur in the nucleus. This 
suggests that nucleo-cytoplasmic shuttling may participate in PARG regulation. 
Functional studies of PARG have been limited and most studies have utilized gene 
disruption (Schreiber et al., 2006). There is still much work to be done to elucidate the 
reasons for two distinct populations of PARG and the potential function of the different 
isoforms. The covalent modification of acceptor proteins by PARP-1 and subsequent 
 
 
alterations by PARG, provide numerous ways to control acceptor protein activity and 
potentially implicate the PARylation reaction mediated by PARP-1 in a number of 
functional roles within the cell. Additionally, PARG has a higher affinity for some types 
of PAR chains (for example, long linear polymers), which results in two distinct 
populations of polymers in the cell (D'Amours et al., 1999). This suggests that the 
heterogeneous PAR forms could have multiple roles in signaling.  
 
MECHANISM FOR DNA DAMAGE DETECTION 
A model of PARP-1 shuttling involves PARP-1 binding damaged DNA via the 
DBD, prompting automodification, which results in a negative charge buildup on PARP-
1 (D'Amours et al., 1999). The charge repulsion results in a gradual loss of affinity for the 
DNA and PARP-1 dissociates, with PAR chains subsequently hydrolyzed by PARG. 
PARP-1 is then able to resume an additional enzymatic cycle when additional DNA 
damage is sensed. Although not specifically mentioned in the model, PARP-1 binding 
relaxes chromatin at the site of DNA damage, which would allow room for repair 
complexes to aggregate (D'Amours et al., 1999). This model does not examine at which 
point PARP-1 is involved in recruiting additional repair proteins to sites of DNA damage, 
which probably occurs while PARP-1 is still associated with the DNA. Additionally, the 
DNA-dependent PARylation of acceptor proteins by PARP-1 also occurs, however, 
whether PAR is added to repair proteins or recognized by repair proteins will require 
further characterization and may be situation specific. 
Upon binding DNA and becoming catalytically active, in addition to 
automodification, PARP-1 is also able to attach to PAR units, to PARylate, other 
 
 
proteins. A specific PAR-binding sequence motif of 20 amino acids has been identified in 
several proteins involved in DNA damage checkpoints and repair including the tumor 
suppressor protein p53, mismatch repair protein MSH6, the repair protein DNA ligase III, 
a scaffolding protein XRCC1, the kinase DNA-PK, a DNA double-stranded break 
response protein Ku70, synthesizing proteins DNA polymerase-ε and -β, and others 
(Burkle, 2001). Notably, several of these proteins are involved in the base excision repair 
(BER) pathway and thus implicate PARP-1 in BER functions within cells. Multiple lines 
of evidence corroborate this claim; notably, PARylation reactions are initiated by the 
types of DNA damage that incites BER activity and PARP-1 inhibition results in BER 
inhibition in vivo  and in vitro (D'Amours et al., 1999). XRCC1, a scaffold protein 
necessary for stimulating BER enzymes, interacts preferentially with automodified 
PARP-1 in vitro, supporting observations in vivo that XRCC1 exhibits PAR-dependent 
recruitment to damaged DNA to incite additional BER activities (Schreiber et al., 2006). 
Additionally, PARP-1 knockout mice treated with DNA damaging agents exhibit 
increased sister chromatid exchanges and chromatid breaks – indicating in addition to a 
role in DNA repair, whole genome stability is affected upon losing PARP-1 function 
(Burkle, 2001).  
 
SITUATION SPECIFIC PARYLATION: DNA DAMAGE 
DNA-damage dependent PAR synthesis has subtle, yet important, differences 
from the schemes typically presented, which more appropriately describe PAR synthesis 
on acceptor proteins. Most importantly, synthesis of PAR after DNA damage has specific 
functions, rather than non-DNA damage dependent synthesis wherein PARylation acts on 
 
 
a less situation-specific basis to modify the activity of nuclear proteins. It has been shown 
that a transient topoisomerase IIβ-induced double stranded breaks (DSBs) resulted in the 
activation of PARP-1, in addition to previous observations by multiple research groups 
that single stranded breaks (SSBs) are able to potently activate PARP-1 (D'Amours et al., 
1999; Ju et al., 2006). In either case, the PAR production resulting from DNA damage 
has distinct functions: PARylation of histones H1 and H2B, PAR mediated signaling of 
DNA damage and recruitment of base excision repair machinery (Schreiber et al., 2006). 
Although the PARylation of histone proteins is functionally the same as previously 
described PAR roles, providing a signal and recruiting additional proteins are alternate 
functions for PAR formation. Research suggests that the level of PARP-1 activation (and 
thus the level of PAR production) due to SSBs or DSBs may serve as a signal for the 
specific type of damage done, with DSBs accumulating more PAR at the site of DNA 
damage (D'Amours et al., 1999). The signal and recruitment functions provide additional 
means for PARP-1 mediated roles within the cell.  
 The first indications for the role of PARP-1 in DNA damage repair came from 
experiments that observed a marked decrease in NAD+ levels in cells exposed to DNA-
damaging agents with a concomitant increase in PAR polymers (D'Amours et al., 1999). 
In three independent studies using knockout mice, it was observed that when disrupting 
different exons of PARP-1, BER occurred at a slower rate and overall genome instability 
increased, as defined by amplified sister chromatid exchange (Shall and de Murcia, 
2000). Furthermore, upon binding breaks in DNA, the catalytic activity of PARP-1 
increases as much as 500-fold over basal levels, implying that DNA damage is an 
important trigger of PARP-1 activity (Kim et al., 2005). Therefore, resultant PAR 
 
 
production could act as a marker for DNA damage in multiple capacities, as previously 
suggested.  
 
CURRENT PARP RESEARCH 
 The most recently published articles indicate PARP inhibition is relevant to the 
therapy of multiple types of cancer.  Several clinical studies are underway investigating 
the therapeutic potential of PARP inhibitors as monotherapy and in combination with 
temozolomide, platinum drugs, topoisomerase poisons, and ionizing radiation 
(Mangerich and Burkle, 2011). As discussed later, the mechanism for PARP inhibition, 
specifically in models using combination therapy with Temozolomide, has been clearly 
elucidated and offers several advantageous features. Additionally, with the advent of 
clinically relevant silencing methods, it may be possible to target specific proteins in 
cancer cells to render them sensitive to chemotherapy drugs.  
The research presented in this thesis investigates clinically relevant silencing 
methods and the effects of temozolomide, PARP-inhibition, and MGMT and PARP-1 
siRNA treatment on four GBM cell lines. There are currently many methods available for 
silencing specific proteins in vitro, but in order for this research to be translatable to 
human studies it was important to find a clinically relevant method for in vivo silencing.  
Next, while TMZ has been established as the standard of care for GBM, in order to do 
additional studies it was necessary to establish a consistent method for creating TMZ 
dose response curves in the cells of interest. Since inhibition of PARP-1 has been 
associated with increased sensitivity to chemotherapy agents like TMZ, the effect of 
PARP-1 inhibition and PARP-1 siRNA treatment was explored. Finally, because the 
 
 
literature shows a strong correlation between MGMT activity and increased resistance to 
TMZ, combination studies were done to compare the most effective method for 
increasing the sensitivity to TMZ in the GBM cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO: RNA INTERFERENCE 
 
 
 
 
RNA interference (RNAi) is a major gene regulation mechanism in eukaryotic 
cells and can be experimentally exploited to silence gene expression through the use of 
exogenous short interfering RNA (siRNA). The clinical application of RNAi is limited, 
however, due to inadequate methods of siRNA delivery and its relative instability 
(Behlke, 2006). Chemical modifications making siRNA more resistant to nuclease and 
nonspecific degradation are variably effective (Elmen et al., 2005). Perhaps more 
pertinent to successful site specific treatment using siRNA are studies examining delivery 
methods, particularly those suitable for human use. While the route of administration will 
be definitive in total dose necessary, tissue distribution, and potential side effects, the 
delivery „vehicle‟ by which the siRNA enters the cell will be the most important variable 
in treatment efficacy.  
Due to the high negative charge density of nucleic acids, cationic polymers, which 
can bind siRNA and neutralize charge to facilitate transport across the cell membrane, 
have gained notoriety as delivery reagents (Behlke, 2006). These reagents do not disrupt 
the cell membrane, and are better suited for clinical use for obvious reasons. 
Polyethylenimine (PEI) is one such cationic polymer currently being used as a siRNA 
delivery vehicle in clinical models. Thus, by examining PEI reagents for silencing 
efficacy in an in vitro GBM model, it may represent a more clinically relevant model for 
translational research.  
 
 
 
RNAi MECHANISM 
 While there had been evidence for post-transcriptional gene silencing, it was the 
work done by Andrew Fire and Craig C. Mello in C. elegans that finally described RNA 
interference (Fire et al., 1998). Eight years after publishing their work, they won the 2006 
Nobel Prize in Physiology or Medicine. In addition to uncovering a new cellular feature 
for controlling genetic information, this discovery transformed the way gene regulation is 
used in laboratory settings. So-called “gene-knockdown” (as opposed to gene-knockout, 
when a gene is removed from the DNA sequence) is now a widely accepted laboratory 
technique to study the function of genes in vitro and in vivo.  
 Gene regulation by RNAi is dependent on short pieces of double stranded RNA 
(dsRNA) complementary to the target mRNA sequences (Davis et al., 2010). The RNA 
molecules can be endogenous, transcribed from RNA-encoding genes to form stem-loop 
structures which are exported to the cytoplasm and typically called micro RNA 
(miRNAs). Exogenous RNAs that participate in the RNAi pathway can be the product of 
a virus or laboratory applications. During laboratory manipulations, the dsRNA used is 
sometimes called siRNA initially, although the distinction is rather insignificant at this 
point.  
 Endogenous and exogenous interfering RNAs initiate the RNAi machinery once 
they are present in the cell‟s cytoplasm. There, both types of RNAs are processed by an 
endoribonuclease enzyme called Dicer. The result of Dicer‟s action is a short dsRNA 
fragment, called a small interfering RNA, with a length of typically 20-25 nucleotides 
and a 3‟ and 5‟ two or three-base overhang. Bioinformatic studies have indicated this 
length reduces nonspecific interactions while increasing the specificity of target gene 
 
 
knockdown (Qiu et al., 2005). After this point the endogenous and exogenous RNAi 
pathways become indistinguishable from one another.  
 The appearance of siRNA in the cytoplasm activates the RNA-induced silencing 
complex (RISC). This occurs via interaction between the short dsRNA and Argonaute, 
the catalytic component of the RISC complex, which results in the separation of the RNA 
strands into single stranded RNAs (Qiu et al., 2005). The complexation of RISC with the 
single stranded RNA allows it to bind to mRNA with complementary sequences. 
Consequently, cleavage of the mRNA occurs and it cannot be used as a template for 
protein translation. Thus, the gene whose protein product was encoded by the 
complementary mRNA is “knocked-down”.  
 
siRNA DELIVERY 
 The delivery of siRNA in an in vitro experiment can be achieved in several 
different ways (Davis, 2009). PEI-based reagents bypass situations where the cell 
membrane must become more permeabilized than normal, because it can be endocytosed 
through normal cellular processes. The cationic PEI polymer, together with negatively 
charged siRNA, forms a complex molecule without a net charge. The complex is released 
when the environment inside the endosome becomes acidic, protonating the siRNA and 
causing electrorepulsion of the cationic polymer.  Although the mechanisms for the 
transport of the siRNA outside of the endosome are not clearly elucidated, hypotheses are 
currently focusing on the disruption of the acidic environment inside the endosome, 
which would normally form a lysosome, as a trigger for the endosome to dissociate and 
release the siRNA into the cell.  
 
 
 In addition to the advantage of this delivery method over cell membrane 
disruption methods, some groups have been able to favorably modify the PEI. These 
modifications include adding a ligand to the terminus of the polymer so that it is targeted 
to specific cell types (Davis, 2009). Incorporating drug delivery with the PEI-siRNA 
complex is also an area of research currently being explored. These and other 
developments will allow for specific cellular targeting mechanisms and have the potential 
to be powerful new treatments.  
 
AIMS 
 There are now many methods available for silencing specific proteins in vitro, and 
previous unpublished research from our laboratory indicated a membrane permeabilizing 
procedure was successful for in vitro silencing. However, it was important to find a 
clinically relevant method for this silencing. The primary goal of this research was to 
determine if a polyethylenimine-based protocol could be used to silence PARP-1, 
MGMT, and combinations of both proteins. In order to complete the primary goal, it was 
necessary to assess presence or absence of the genes of interest and establish gene 
expression levels before and after silencing the proteins of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
 
 
 
CELL CULTURE 
 
 Four human glioma cell lines were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). Cells were cultured in Minimum Essential Medium – 
Eagles (MEME), purchased from the ATCC, and 10% Fetal Bovine Serum (FBS) 
(Lonza, Basel, Switzerland) was added as a supplement for cell growth. All cell cultures 
were grown in a humidified incubator at 37°C and 5% CO2 atmosphere. Cells flasks were 
25 cm
2 
and cells were plated at 500,000 cells per flask in 10 mL complete media. Cell 
cultures were maintained in the humidified incubator and passed when cell monolayers 
reached 80-90% confluency. For transfer to a 96-well plate, cells were plated at 10,000 
cells per well in 100 L complete media.  
 The LN-229 cell line (ATCC# CRL-2611) was isolated in 1979 from a 
glioblastoma in the right frontal parieto-occipital complex of a 60-year old white woman 
(Diserens AC, et al., 1981). Oncogene characterization has shown that this cell line has 
mutated p53, wild type PTEN and deletions of p16 and p14ARF (Ishii et al., 1999). The 
T98-G cell line (ATCC# CRL-1690) comes from a 61-year old Caucasian male 
glioblastoma sample. Cytogenetic analysis of this cell line has shown hyperpentaploid 
chromosome count with numerous structural alterations (Olopade et al., 1992).  The U-
138MG cell line (ATCC# HTB-16) was acquired from grade IV glioblastoma in a 47 
year old Caucasian male. This cell line also exhibits polyploidy, ranging from 
hyperdiploid to pentaploid chromosomes (Olopade et al., 1992). The final cell line, U-
 
 
87MG (ATCC# HTB-14) was cultured from a grade IV glioblastoma in a Caucasian 44 
year old female and usually exhibits hypoploidy (Beckman G, et al., 1971). 
  
SILENCING 
 For siRNA transfection, the cationic polyethylenimine-based  polymer regent 
INTERFERin™ (Polyplus, New York, NY) was used. The protocol from the 
manufacturer was used for all experiments, with a modification for a final concentration 
of 10 nM siRNA in each treatment well. The PARP-1 siRNA used was obtained from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and consisted of a pool of three human 
target-specific 20-25 nucleotide siRNAs. The siRNA for Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and MGMT were obtained from Applied Biosystems/Ambion 
(Austin, TX). All siRNAs were diluted to 10 M working solutions.  
For the silencing protocol, 0.17 L of 10 M siRNA was mixed by pipetting with 
50 L MEME, per well. Then, 0.75 L of INTERFERin™, per well, was added to the 
siRNA solution.  These solutions were made as master mixes and scaled by number of 
treatment wells necessary. Once combined, the reagents were mixed immediately by 
vortexing for 10 seconds. Following this, the siRNA treatment solution was incubated for 
10 to 30 minutes at room temperature. During the incubation, the old media in the 96-
well plate was removed and replaced with 125 L of new, complete media. Finally, 50 
L of the siRNA treatment solution was added to each well by experimental treatment 
group.  
 
 
 
 
 
RNA EXTRACTION 
 For RNA extraction from cell culture flasks, the cells were removed by gently 
scraping and transferred by pipette to a 15 mL centrifuge tube. Cell pellets were formed 
by centrifuging at 10,000 x g for 10 minutes and the supernatant was removed. Next, the 
cells were resuspended in 5 mL sterile phosphate buffered saline (PBS), pH 7.4, to wash 
away any remaining media. The cells were counted with a hemocytometer and an aliquot 
representing 30,000 cells removed for RNA extraction. If necessary, the volume of cells 
in PBS was increased to 300 L, or the cells were centrifuged in a 1.5 mL 
microcentrifuge tube at 10,000 x g and subsequently resuspended to reduce the volume of 
PBS to 300 L.  
 The following protocol for RNA extraction has been adapted from the 
manufacturer‟s RNeasy Kit “Purification of cytoplasmic RNA from animal cells” 
protocol (Qiagen, Valencia, CA). Briefly, 300 L of RLT buffer was added to the cells 
and mixed thoroughly by pipetting. This solution was transferred to a QIA shredder and 
centrifuged for 2 minutes at 10,000 x g. Then, 300 L of ethanol (96-100%) was added to 
the lysate and this solution was transferred to an RNeasy spin column, which was 
centrifuged at 10,000 x g for 15 seconds. The collector was replaced and 600 L RW1 
buffer was added to the column and centrifuged for an additional 15 seconds at 10,000 x 
g. Afterward, the collector was replaced and 400 L RPE buffer was added to the spin 
column and centrifuged at 10,000 x g for 15 seconds. This was repeated once more, with 
centrifugation at the same speed for 2 minutes. The column was then placed into a new 
collector and the RNA was eluted by adding 45 L of nuclease free water and 
 
 
centrifuging for 1 minute at 10,000 x g, and repeating once. The RNA in the collector 
was then transferred to a labeled 1.5 mL microcentrifuge tube and stored at -80°C.  
 For RNA extraction from 96-well plates, the protocol differs slightly. Briefly, the 
media was removed from the wells using a micropipettor, and 100 L RLT buffer was 
added to each well. The wells were gently scraped with a micropipettor tip to ensure 
maximal detachment of cells from the plate. The cells were collected in triplicate (groups 
of three wells), so that the RNA extracted was from 30,000 cells. Thus, three wells‟ 
worth of cells and RLT buffer is added to each QIA shredder, resulting in a final volume 
of approximately 300 L. After this step, the protocol was the same as previously 
described for cell culture flasks. 
 
REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION 
 End-point gene expression was verified using reverse-transcriptase polymerase 
chain reactions (RT-PCR) at 24 hours after silencing treatment (48 hours after plating). 
Control groups were plated for 48 hours before analysis. The Access RT-PCR System 
(Promega, Madison, WI) was used according to their published protocol. Briefly, each 
reaction mix contained the following: 9 L sterile water, 25 L AccessQuick™ Master 
Mix (2X), 1 L AMV reverse transcriptase (5u), 5 L forward primer (10 M), 5 L 
reverse primer (10 M), and 5 L of extracted RNA sample. The reverse transcription 
and PCR amplification conditions were set as indicated in the manufacturer‟s “Standard 
RT-PCR” protocol.  
 Custom primers were designed and purchased from Integrated DNA Technologies 
(IDT, Coralville, IA) for MGMT and PARP-1. The MGMT primer sets had a forward 
 
 
primer sequence of 5‟-AGGAGCAATGAGAGGCAATCCTGT-3‟, and a reverse 
sequence of 5‟-AGGGCAGCGTTAGAGAAGGAAACA-3‟. The forward sequence for 
the PARP-1 primer set was 5‟-TGCAAGAAATGCAGCGAGAGCATC-3‟, with a 
reverse sequence of 5‟-TGGATGGTACCAGCGGTCAATCAT-3‟. Both primer sets had 
melting temperatures of 60.3°C, with the exception of the PARP-1 forward primer, which 
had a melting temperature of 60.2°C. Both of these primers were diluted to 10 M 
working solutions.  
A stock GAPDH primer set was also obtained from IDT. The forward sequence 
for the GAPDH primer was 5‟-AAGGTCGGAGTCAACGGATTTGGT-3‟, and the 
reverse primer sequence was 5‟-AGTGATGGCATGTGTGGTCAT-3‟. The melting 
temperature of these primers was 60.5°C. These primers were also diluted to a working 
solution of 10 M.   
 
GEL ELECTROPHORESIS 
 Gels were prepared to be 2% agarose in 1X Tris/Borate/EDTA (TBE) buffer, with 
1 L ethidium bromide per 100 mL TBE. The samples were prepared for loading by 
adding 5 L of 10X loading dye (1/10 total sample volume). In each well, 15 L of the 
sample was loaded. For the ladder, a 100 bp exACTGene PCR ladder (Fisher 
BioReagents, USA) was used, with 10 L loaded as needed. Depending on the size of the 
gel, electrophoresis run time was either 45 minutes (small) or 80 minutes (large), both at 
100 volts for the duration of run time. Results were visualized under UV light, using 
Kodak imaging software (Kodak, Rochester, NY). 
 
 
 
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION 
Relative gene expression was quantified using real-time PCR (qRT-PCR) using 
the Applied Biosystems StepOne 48-well block real-time PCR thermocycler (Foster City, 
CA) with reagents from the same company. Baseline analysis was performed on cells that 
had been plated for at least 24 hours. Pre-designed gene expression assays with FAM 
labeling from Applied Biosystems specific for PARP-1 (Assay ID Hs00911379_g1), 
MGMT (Assay ID Hs00172470_m1), and GAPDH (Assay ID Hs99999905_m1) were 
used. The manufacturer‟s protocol for the TaqMan One-Step RT-PCR Master Mix 
(Applied Biosystems) was used without any changes. Cycling began with a hold at 50⁰C 
for two minutes, followed by 95⁰C for ten minutes and forty cycles of 15 seconds at 
95⁰C, one minute at 60⁰C ran afterwards.  
 
STATISTICAL ANALYSIS 
 Data from qRT-PCR reaction was analyzed using LineReg 2.0 software 
provided by Applied Biosystems to establish relative quantity gene expression levels. 
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to perform 
statistical analysis on relative gene expression values. A one way ANOVA with a Tukey 
post test was used for comparison. Significance was one asterisk (*) if p<0.05, two (**) if 
p<0.01 and three (***) if p<0.001. 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
To verify the presence and activity or absence of each gene of interest, reverse 
transcriptase PCR and subsequent gel electrophoresis were performed on mRNA 
extracted from each cell line. The genes of interest were the endogenous control GAPDH, 
and the two target genes PARP-1 and MGMT. As shown in Figure 1 (Appendix A), all 
cell lines were positive for GAPDH mRNA. The presence of PARP-1 mRNA was readily 
apparent in each of the four cell lines. Finally, MGMT mRNA was also determined to be 
present, as evidenced by amplification in each of the cell lines.  
After verifying the endogenous control and the presence of each of the genes of 
interest, PARP-1 and MGMT, several silencing studies were undertaken. Figure 2 shows 
the result from a 24 hour MGMT siRNA treatment using the INTERFERin™ protocol in 
U-138 cells. The relative quantity of MGMT gene expression for U-138 cells treated with 
MGMT siRNA for 24 hours was significantly reduced when compared to the untreated 
U-138 control (P=0.0031). Decreased expression of MGMT after siRNA treatment was 
also observed at 24 hours in the T-98 cell line (Figure 3). These results are representative 
of what would be expected in the other two cell lines after 24 hour treatment with MGMT 
siRNA. 
The duration of the siRNA silencing was determined by assessing relative gene 
expression quantity over several time points. As shown in Figure 3, MGMT silencing 
was achieved in T-98 cells at three consecutive time points: 24 hours, 48 hours, and 72 
hours. Relative to the untreated T-98 control, cells treated with MGMT siRNA showed 
 
 
significantly decreased levels of MGMT expression (P=0.0008). However, at no time 
point was the MGMT expression significantly different from another time point.  
Baseline PARP-1 expression level for all four cell lines was established. The 
relative quantity of PARP-1 was highest in the U-87 cell line (Figure 4). The lowest 
PARP-1 gene expression level relative to the U-87 cell line was found in the U-138 cell 
line. The other two cell lines, LN-229 and T-98, had much lower PARP-1 gene 
expression levels than the U-87 cell line. These results agree with the RT-PCR results 
shown in Figure 1, showing that PARP-1 is expressed in all four cell lines. 
After establishing the presence and relative gene expression for PARP-1 in each 
of the cell lines, the INTERFERin™ silencing protocol was used to silence PARP-1. 
Figure 5 shows PARP-1 silencing at a single time point in the LN-229 cell line. The 
PARP-1 gene expression in LN-229 cell treated with PARP-1 siRNA for 24 hours was 
65% lower when compared to the untreated LN-229 control sample. Similar decreases in 
PARP-1 gene expression levels relative to the untreated controls at the 24 hour time point 
were found in the U-138 and T-98 cell lines. 
PARP-1 silencing was shown to persist over multiple time points similar to the 
MGMT silencing. Shown in Figure 6, PARP-1 silencing persisted in T-98 cells over three 
consecutive time points: 24 hours, 48 hours, and 72 hours. Levels of PARP-1 gene 
expression were significantly reduced (P=0.0003) relative to the untreated T-98 control 
cells. From the 24 hour sample to the 72 hour sample, it appears the PARP-1 gene 
expression continues to decrease relative to the untreated T-98 control. Finally at 72 
hours the PARP-1 gene expression was virtually undetectable in the T-98 cells.  
 
 
After demonstrating that both MGMT and PARP-1 could be silenced using 
siRNA it was of interest to determine whether silencing of MGMT and PARP-1 could be 
established concurrently in cells using the INTERFERin™ protocol. Gene expression of 
MGMT after combination silencing is shown in Figure 7. Compared to the untreated U-
138 control, cells administered a treatment containing only MGMT siRNA showed 
significantly (P=0.0002) diminished MGMT gene expression (Figure 7). For U-138 cells 
treated with both MGMT and PARP-1 siRNA at the same time, a significant decrease in 
MGMT gene expression was observed (P=0.0002). When compared to each other, single 
MGMT siRNA treatment and combined MGMT and PARP-1 siRNA treated cells had 
similarly decreased levels of MGMT expression, and did not differ significantly.  
PARP-1 gene expression after combination silencing was assessed. The U-138 
cells treated with only PARP-1 siRNA showed significantly lower levels of PARP-1 gene 
expression when compared to the untreated control cells (Figure 8). When U-138 cells 
were treated with both PARP-1 and MGMT siRNA, the PARP-1 gene expression level 
was significantly reduced relative to the untreated U-138 control. The silencing 
treatments, single or combined siRNAs, were not significantly different from one 
another. 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 All four cell lines were positive for the endogenous control gene GAPDH, and its 
mRNA product. This indicates that the gene was being actively transcribed into mRNA 
and the extraction of RNA and amplification of mRNA was successful in all four cell 
lines. Furthermore, each cell line was positive for mRNA from the PARP-1 gene (Figure 
1). By using qRT-PCR, it was shown that the levels of PARP-1 gene expression between 
the four cell lines varied (Figure 4). Finally, all cell lines were also shown to have mRNA 
from the MGMT gene, indicating the MGMT gene was actively transcribed. This was 
expected, as expression levels had previously been quantified by qRT-PCR for these four 
cell lines (Davis, 2008).  
 Silencing was established for MGMT in two cell lines (Figures 2 and 3). The 
levels of MGMT gene expression after silencing in the cell lines was significantly 
reduced after MGMT siRNA treatment using the INTERFERin™ protocol. The reduction 
in MGMT gene expression was quantifiably lower over three consecutive time points 
when compared to the untreated control cells (Figure 3). No time points showed 
significant differences in MGMT gene expression levels from one another. Similar results 
for MGMT siRNA treatment would be expected in the other two cell lines, U-87 and 
LN229. 
 It was also determined that PARP-1 could be silenced in three of the four cell 
lines (Figures 5, 6, and 8). After PARP-1 siRNA treatment, the gene expression levels 
were diminished to varying degrees between cell lines at the 24 hour time point (Figures 
5, 6, and 8). Additionally, the reduction in PARP-1 gene expression levels appeared to be 
 
 
stable over three time points in the T-98 cell line (Figure 6). As shown, in one instance, 
PARP-1 gene expression was practically abolished at the 72 hour time point (Figure 6). 
We assume PARP-1 siRNA treatment would produce similar results at 24 hours in the U-
87 cell line. Furthermore, similar results would be expected for the other three cell lines 
(U-87, U-138, and LN-229) for gene expression levels after PARP-1 siRNA treatment at 
three time points.  
Together, these silencing time trials indicate that MGMT and PARP-1 siRNA 
administered with the INTERFERin™ protocol can be used to silence the target genes of 
interest. In addition, the relative quantity of gene expression shows significantly reduced 
levels when cells are treated with either type of siRNA or in combination (Figures 7 and 
8). The reduction in gene expression of both MGMT and PARP-1 targets was also stable 
over three time points in the T-98 cell line (Figures 3 and 6). Moreover, the reduction in 
expression of each target gene is comparable to the reduction in the other and this trend 
continues at consecutive time points. 
Furthermore, the INTERFERin™ protocol was used to successfully silence 
PARP-1 and MGMT at the same time when administered as a combination treatment 
(Figures 7 and 8). When compared to gene expression levels in untreated cells, the 
combination treatment significantly reduced the relative quantity of gene expression of 
both MGMT and PARP-1 targets. Additionally, the reduction in gene expression of either 
target was comparable to the reduction observed when treating with either MGMT or 
PARP-1 siRNA alone. Similar results would be expected in the other three cell lines, 
especially in light of the reduction of gene expression after single siRNA treatment in the 
T-98 and LN-229 cell lines. 
 
 
Overall, the PEI-based INTERFERin™ silencing protocol was successful when 
used for single siRNA applications or combination siRNA treatments. Silencing of either 
MGMT or PARP-1 targets was successful in three of the four cell lines. Simultaneous 
silencing of MGMT and PARP-1 was achieved in one of the four cell lines, and a 
significant reduction in gene expression levels at three consecutive time points was 
achieved in one of the four cell lines for single siRNA treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE: TEMOZOLOMIDE 
 
 
 
 
 Temozolomide (TMZ) is currently the chemotherapy drug of choice for treating 
newly diagnosed and refractory GBM (Stupp et al., 2005). A methylating agent, TMZ 
(chemical structure: 3,4-dihydro-3-methyl-4-oxoimidaso[5,1-d]-1,2,3,5-tetrazine-8-
caboxamide) works by spontaneously hydrolyzing into the active intermediate 5-(3-
methyltriazen-1-yl)imidazole-4-carboxamide (MITC) during liver metabolism. The high 
oral bioavailability and low bone marrow toxicity of TMZ makes it more favorable than 
its structural analogue dacarbazine, with extensive tissue distribution and the ability to 
cross the blood brain barrier (Newlands et al., 1997). Consequently, TMZ is used both as 
a single agent and in combination with radiotherapy in the treatment of certain types of 
cancer. 
 
ACTION OF TEMOZOLOMIDE 
The result of DNA methylation by TMZ is methyl adducts on three different 
positions: N
7
-methylguanine (~70%), N
3
-methyladenine (~9%), and O
6
-methylguanine 
(~5%) (Villano et al., 2009). At the O
6
-methylguanine position, antitumor activity 
becomes inversely correlated to the expression levels of the DNA repair enzyme MGMT 
(Yip et al., 2009). Resistance to TMZ occurs as MGMT is able to remove the DNA 
methyl adduct and transfer it to an internal cysteine residue, which inactivates the MGMT 
protein. Clinical studies investigating the methylation status of MGMT have corroborated 
the relationship between benefit from TMZ and a methylated MGMT promoter as well as 
the resistance to TMZ conferred by an active promoter for MGMT (Hegi et al., 2005).  
 
 
 The antitumor activity of the O
6 –methylguanine position is the result of several 
molecular processes. Since the methylated base appears to be an adenine to DNA 
polymerases, the base is incorrectly paired with thymine, which the mismatch repair 
(MMR) proteins MSH2 and MSH6 recognize and subsequently bind the mispairing 
(Mojas et al., 2007).  Once repair ensues, the MMR proteins reinsert a thymine base 
instead of cytosine opposite the O
6 –methylguanine and mismatch processing repeats 
itself creating a futile cycle. Eventually the MMR cycling creates a single stranded break 
in the DNA, later leading to doubles stranded breaks and apoptosis (Villano et al., 2009).  
 
AIMS 
TMZ has been established as the standard of care for malignancies in the central 
nervous system (CNS), including GBM.  In order to do additional studies it was 
necessary to establish a consistent method for creating TMZ dose response curves in the 
four cell lines of interest. The primary goal was to 1) determine the dose-dependent cell 
response to temozolomide for each of the four cell lines; 2) determine the dose-dependent 
response at three time points – 24, 48, and 72 hours; and finally, 3) determine the 
effective concentration of TMZ that killed 50% of the cells for each cell line (EC50). 
Additionally, a secondary goal was to establish a procedure for conducting TMZ dose 
response curves that can be replicated. 
 
 
 
 
 
 
METHODS 
 
 
 
CELL CULTURE 
 The four human glioma cell lines obtained from the ATCC were cultured as 
previously described. For the TMZ dose response assays, cells were transferred to a 96-
well plate, and plated at 5,000 cells per well in 100 L of complete media. To ensure the 
accurate plating of cells, after centrifugation and during resuspension of the cells, a cell 
strainer was used to ensure single cell suspension before plating in the 96-well plate. To 
decrease pipetting errors, the cells were plated using a repeating pipettor. The plated cells 
were then allowed to incubate for 24 hours before the initial TMZ treatment to ensure 50-
70% confluency within the experimental wells.  
 
TEMOZOLOMIDE DOSE RESPONSE ASSAY 
 Temozolomide (TMZ) was purchased from Sigma-Aldrich (St. Louis, MO) and 
carefully dissolved in 100% dimethyl sulfoxide (DMSO) to a concentration of 400 mM to 
create a stock mixture. To ensure the maximal homogenization of TMZ and DMSO, the 
mixture was vigorously vortexed and repeatedly mixed with a micropipettor. The stock 
TMZ solution was subsequently used to make a master mix of 2000 M TMZ (0.05% 
DMSO) in complete media (MEME + 10% FBS). The 2000 M TMZ master mix was 
used to create a serial dilution of TMZ in complete media in the following 
concentrations: 1600 M, 1200 M, 800 M, 640 M, 400 M, 320 M, 200 M, and 
160 M. Each solution was vortexed for at least 10 seconds and repeatedly mixed with a 
 
 
micropipettor to ensure homogenization. A control solution of 0.05% DMSO in complete 
media was also prepared.   
 At 24 hours after plating, the original complete media on the cells was removed 
using a multichannel micropipettor, being careful not to disturb the confluent cells. Next, 
media containing the different treatment concentrations of TMZ, the DMSO control, or a 
negative control of complete media was added to the cells. The time the cells were 
without any media never exceeded 15 minutes. The final volume of treatment solutions in 
the wells was 100 L. There were triplicate wells for each treatment group. All plates 
were kept in an incubator at 37°C and 5% CO2 atmosphere for the duration of the 
treatment time, with separate plates for each time point. 
 
CELL VIABILITY ASSAY 
 The CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI) 
was used to determine the number of viable cells after treatment.  CellTiter-Glo® Buffer 
was thawed and used to resuspend the CellTiter-Glo® Substrate. This mixture was 
allowed to reach room temperature before use. Inversion of the reagents was sufficient to 
form a homogenous solution, and then allowed to stand while the plates equilibrate to 
room temperature. Equal amounts of CellTiter-Glo® Solution were added to the same 
amount of cell culture medium within each experimental well, 100µL for this experiment. 
An orbital shaker was used to mix the CellTiter-Glo® Solution completely with the 
media already present in the well. After two minutes of mixing, the plate was incubated 
at room temperature for 10 minutes. Finally, luminescence was determined using a 
 
 
Turner Biosystems Modulus® Microplate Reader (Sunnyvale, CA) at 24, 48, or 72 hours 
after treatment, with triplicate wells for each experimental group within a cell line.  
 
STATISTICAL ANALYSIS 
 Luminescence values from the Cell-Titer Glo® protocol were converted to 
survival percentages relative to the untreated control survival values. The doses of 
temozolomide were transformed from micromolar values using the equation X=Log[X]. 
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to plot relative 
survival values against the transformed temozolomide doses to generate a dose response 
curves using a sigmoidal line of best fit. EC50 values were calculated from the best fit 
curves and analyzed using a repeated measures ANOVA with a Tukey post test. Graphs 
of EC50 values show the standard error of the mean (SEM). Significance was one asterisk 
(*) if p<0.05, two (**) if p<0.01 and three (***) if p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 Dose dependent responses to temozolomide were characterized in all four cell 
lines (LN-229, T-98, U-87, and U-138). The temozolomide dose response assay was 
performed as described previously, and survival data was generated using the Cell-Titer 
Glo® protocol and luminescence was recorded. Figure 9 shows the results from a 24 hour 
treatment of four cell lines with increasing concentrations of TMZ (from untreated, 0 µM, 
to the highest treatment group, 2000 µM). When analyzed, the null hypothesis that the 
sigmoidal dose response curves would be the same for each cell line, was rejected 
(P<0.0001). There were five outliers excluded from this analysis (3 from the U-87 cell 
line and 2 from the U-138 cell line) leaving 103 samples. 
 Dose response curves were generated for each of the four experimental cells lines 
at each time point: 24, 48, and 72 hours (Figures 10 and 11). There were no outliers in 
either the 48 hour or the 72 hour analysis and statistical analysis indicated a significant 
difference between each of the cell lines at 48 hours (P<0.0001). At 72 hours, there was 
no difference in response (P=0.1508).  
 Dose response curves were also analyzed by cell line for each time point. For the 
U-87 cell line, the curves were significantly different at each time point, P<0.0001, as 
shown in Figure 12, and no outliers were found. The U-138 cell line also had 
significantly different curves at each of the three time points (P=0.0264) with no outliers 
reported (Figure 13). Figure 16 shows the dose response curves for the T-98 cell line, 
which also had no outliers, however, the curves at different time points were not 
significantly different from each other (P=0.2748). For the LN-229 cell line, depicted in 
 
 
Figure 15, the curves were significantly different at each time point with no outliers 
(P=0.0102). 
From the TMZ dose response curves, the effective concentration (EC50) of TMZ 
that killed 50% of the cells was determined for each cell line (Figure 16). The effective 
concentration (EC50) of TMZ was determined for each cell line from the dose response 
curves generated at 24 hours. Statistical analysis indicated that the EC50 values differed 
significantly for all cell lines (P>0.0001). The U-87 median EC50 was 410.6 µM TMZ, 
and had the most significantly different EC50 values when compared to the other cell 
lines. The U-138 cell line median EC50 was 1135 µM TMZ. The T-98 cell line had a 
median EC50 of 1364 µM TMZ, and the LN-229 cell line had a median EC50 of 736.9 µM 
TMZ. 
This analysis was also performed on the EC50 values at the 48 and 72 hour time 
points (Figures 17 and 18, respectively). The ANOVA for the 48 hour experiment 
indicated there were differences between the EC50 values for the four cell lines 
(P>0.0001). At 48 hours, the U-87 median EC50 increased to 970.0 µM TMZ, and was 
significantly different when compared to the T-98 cell lines and the LN-229 cell line but 
not the U-138 cell line. The U-138 cell line median EC50 decreased to 860.0 µM TMZ, 
and differed from both the T-98 and LN-229 cell lines. The T-98 cell line median EC50 
was similar to the 24 hour value, at 1305 µM TMZ, and was significantly different from 
the LN-229 cell line, whose median EC50 decreased at 48 hours to 543.7 µM TMZ.  
The ANOVA performed on the EC50 values of the four cell lines at 72 hours 
showed that there was no significant difference (P=0.0659) (Figure 18). The median EC50 
value for the U-87 cell line was 859.5 µM TMZ, which was a slight decrease from the 48 
 
 
hour value, but almost double the 24 hour value. For the U-138 cell line, the median EC50 
value was 696.0 µM TMZ, which was a decrease from the 48 and 24 hour values. In the 
T-98 cell line, the median EC50 value was 1048.0 µM TMZ, which was a slight decrease 
from the 24 and 48 hour values. The LN-229 cell line had a median EC50 value of 811.9 
µM TMZ at 72 hours, which was an increase from the 24 and 48 hour values. When the 
T-98 cell line is excluded from the analysis, the differences are significant (P<0.0001). 
The U-87 has a significantly higher EC50 than the U-138 and LN-229 cell lines and, the 
U-138 cell line has a significantly lower EC50 value than the LN-229 cell line. 
After comparing the cell lines to each other at all three time points, the cell lines 
were analyzed by time point. Figure 19 shows the EC50 values for U-87 cells at 24, 48, 
and 72 hours. The 24 hour EC50 differed significantly, but the 48 and 72 hour values were 
not significantly different from each other. The U-138 cell line EC50 differed significantly 
at all three time points (P<0.0001). The T-98 cell line had EC50 values that did not differ 
(P=0.3262); (Figure 21). The LN-229 cell line had EC50 values that were significantly 
different from one another (P=0.0053) (Figure 22). EC50 values differed at 24 and 48 
hours and 48 and 72 hours, but did not differ when comparing 24 and 72 hour time 
points.  
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 Dose dependent responses to Temozolomide were characterized in all four cell 
lines (LN-229, T-98, U-87, and U-138) (Figures 9, 10, and 11). In addition, a dose 
response curve was created for each cell line at three different time points: 24, 48, and 72 
hours (Figures 12, 13, and 14).  Because the cell lines were derived from four different 
tumors, it was not surprising that the response, as indicated by the dose response curves, 
would be different for each cell line. There were significant differences in the dose 
response curves at 24 and 48 hours, as expected (Figures 9 and 10). However at 72 hours, 
the curves were not significantly different (Figure 11).   
 Using the dose response curves to TMZ, the effective concentration (EC50) values 
were calculated for each cell line at three time points, 24, 48, and 72 hours (Figures 16, 
17, and 18). When the EC50 value was compared between cell lines, it was expected that 
the values would be different from each other at each time point. Like the dose response 
curve analysis, the values were significantly different from each other at the 24 and 48 
hour time points (Figures 16 and 17), but not at 72 hours (Figure 18).  
 There were several changes in EC50 values over time in the cell lines. At 24 hours, 
the T-98 and U-138 cell lines had the highest EC50 values, followed by the LN-229 cell 
line, and the U-87 line had the lowest EC50 (Figure 16). At 48 hours, the LN-229 had the 
lowest EC50, the U-138 and U-87 cell lines have the next highest EC50 values 
respectively, and the T-98 cell line again had the highest EC50 value (Figure 17). At 72 
hours, the T-98 cell line appears to continue to have the highest EC50 value, but also has 
the largest standard error (Figure 18). The U-138 cell line had the lowest EC50 value, 
 
 
followed by the LN-229 line, which had an EC50 value very close to the U-87 cell line. 
However, when the T-98 cell line is excluded from the analysis, the differences in EC50 
values between the remaining cell lines is significant, with the U-87 having a 
significantly higher EC50 than the U-138 and LN-229 cell lines. In addition, the U-138 
cell line has a significantly lower EC50 value than the LN-229 cell line.  
When the EC50 values are analyzed by cell line, some patterns appear. The U-138 
EC50 values significantly decrease over the three time points (Figure 20). This pattern 
also appears in the T-98 cell line; however, the differences were not significant, 
presumably because of the large standard error in the 72 hour EC50 value (Figure 21). The 
EC50 values for the LN-229 cell line significantly decrease from the 24 to 48 hour time 
points, however, significantly increase from the 48 to the 72 hour time point (Figure 22). 
The values at 24 and 72 hours for the LN-229 cell line were not significantly different 
from one another. The opposite pattern appears in the U-87 cell line, where the 24 hour 
EC50 value was significantly lower than the 48 and 72 hour values (Figure 19). Although 
it appears that the EC50 value decreases from 48 to 72 hours, it was not significantly 
different.  
 Overall, generating dose response curves for all of the cell lines at three different 
time points was successful (Figures 12, 13, 14, and 15). It was also possible to calculate 
EC50 values for the four cell lines at all time points (Figures 16, 17, and 18). With the 
exception of the large variability in the 72 hour dose response curve for the T-98 cell line 
(Figures 18 and 21), the curves and calculated EC50 values were significantly different 
between cell lines, as expected. For most of the cell lines, the 72 hour EC50 value was 
lower than the 48 hour value (excepting the LN-229 cell line) (Figures 19, 20, 21, and 
 
 
22). Finally, the procedure for conducting TMZ dose response curves appears to be 
sufficiently established and is replicable according to the results from these twelve 
experiments (Figures 9 through 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR: PARP INHIBITION 
 
 
 
 
 PARP-1 inhibitors are instrumental in defining biological roles for PARP-1. They 
are also emerging as effective cancer treatments. Three outcomes of PARP-1 activation 
have been identified that have particular importance in drug development (Jagtap and 
Szabo, 2005). First, as previously indicated, PARP-1 plays a role in the response to DNA 
damage through recruitment of proteins for BER-mediated DNA repair. Additionally, in 
situations of vast DNA damage, PARP-1 can deplete cellular energy pools by using 
copious amounts of NAD+ to synthesize PAR, resulting in necrotic cell death. Third, as a 
transcriptional coactivator of pro-inflammatory response genes, PARP-1 has been 
implicated in the pathogenesis of inflammatory diseases. By inhibiting PARP-1 mediated 
BER repair of DNA, conserving energy for apoptotic cell death and decreasing the 
inflammatory response thereafter, PARP-1 inhibition as an adjuvant therapy in cancer 
treatment could decrease adverse side effects and potentiate the effect of DNA damaging 
chemotherapy agents (Curtin, 2007).  
 PARP-1 has now been studied under various conditions: inhibition using substrate 
analogs, genetic disruption of the PARP-1 in knockout mice, a second generation of more 
potent inhibitors and silencing using RNAi technology (Cheng et al., 2005; Shall and de 
Murcia, 2000). The first PARP-1 inhibitors were based on the structure of its substrate, 
NAD+, using substituted benzamides, most notably the classical PARP inhibitor 
compound, 3-aminobenzamide (3-AB) (Curtin, 2005). Development of second generation 
inhibitors identified three structural features necessary for increased potency which 
resulted in PARP-1 inhibitors currently under testing in clinical trials, such as 
 
 
AGO14699, INO-1001 and GPI 221016 (Ratnam and Low, 2007). Additionally, PARP-1 
knockout mice and silencing technologies have been used to assess responses to ionizing 
radiation and alkylating agents, which were the first observations of chemo- and radio-
sensitization when PARP-1 was absent (Shall and de Murcia, 2000). The results of these 
studies provided the basis for proof of principle trials of PARP-1 inhibitors as an adjuvant 
therapy, many of which have progressed to phase I and phase II clinical trials.  
 
INHIBITION AS CANCER THERAPY 
The role of PARP-1 in BER has some interesting implications in the repair of 
damaged DNA in cells where homologous recombination is deficient. BRCA1 and 
BRCA2 are tumor suppressor proteins that play an important role in repairing DSBs by 
homologous recombination and, when mutated, are known to predispose breast and 
ovarian cancers (Bryant et al., 2005). Loss of PARP-1 in cells gives rise to increased 
sister chromatid exchange, which suggests the loss of BER results in the formation of 
DNA lesions that are repaired by homologous recombination. PARP-1 inhibition in 
BRCA2-deficient cells was shown to lead to spontaneous replication fork collapse and 
trigger of homologous recombination when SSBs in DNA were detected, as evidenced by 
more γ-H2AX foci and increased RAD51 foci (Bryant et al., 2005). Another group found 
that using a PARP inhibitor significantly sensitized BRCA1- and BRCA2-deficient cells 
to DNA damage by increasing the persistence of DNA lesions, and ultimately leading to 
cell cycle arrest and subsequent apoptosis (Farmer et al., 2005).  
These studies have identified a synthetic lethality, where BER deficiency or 
homologous recombination alone does not cause tumor cell death (Tucker and Fields, 
 
 
2003). Recent research indicates PARP inhibitors may be used as single agents in the 
treatment of breast cancers with BRCA mutations (Bryant et al., 2005; Farmer et al., 
2005). Instead, by exploiting the defect in homologous recombination of BRCA1- and 
BRCA2-deficient cells and inhibiting PARP-1 dependent BER of SSBs, tumor cells can 
be specifically targeted for cell death (Bryant et al., 2005; Farmer et al., 2005). The 
specificity for tumor cells occurs when they are homozygous for the loss of BRCA1 or 
BRCA2, and normal cells retain homologous recombination (HR) ability because they 
are heterozygous for these genes. By targeting a pathway that is not lethal in healthy 
cells, PARP inhibition could be a highly specific treatment in BRCA-mutated breast 
cancers and other cancers that show defects in homologous repair. In addition, this may 
have an impact on other pathways that cause HR deficiency, such as loss of function of 
check-point activating kinases ATM and ATR, RAD51, and others (Mangerich and 
Burkle, 2011).  
 There is an alternate rationale for using PARP inhibitor in cancer treatment as 
adjuvants to DNA-damaging chemotherapy drugs and radiotherapy. Classical cancer 
therapies cause damage to DNA, which when left unrepaired, causes cell death. 
Considering the previous discussion of PARP-1‟s involvement in DNA damage repair 
pathways like BER, inhibition of PARP-1 likely contributes to the sensitization of tumor 
cells to cytotoxic drugs and ionizing radiation. This principle is the basis for multiple 
preclinical and clinical studies with PARP inhibitors in combination with classical 
therapies (Mangerich and Burkle, 2011).  
 
 
 
 
AIMS 
Inhibition of PARP-1 has been associated with increased sensitivity to 
chemotherapy agents like TMZ, and some studies have indicated PARP inhibition could 
be a beneficial adjuvant in treating GBM (Horton et al., 2009; Tentori et al., 2005).  The 
primary goal was to compare the response to TMZ in GBM cell lines treated with either 
1) single agent TMZ, 2) TMZ and the classical PARP inhibitor 3-aminobenzamide (3-
AB), or 3) single agent TMZ and PARP-1 siRNA treatment. A secondary goal was to 
compare the response to adding a PARP inhibitor (3-AB) or silencing PARP-1 to 
concurrent TMZ treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
 
 
 
CELL CULTURE 
 The four human glioma cell lines obtained from the ATCC were cultured, as 
previously described. For the PARP-1 inhibition (PARPi) dose response assays, cells 
were transferred to a 96-well plate and plated at 5,000 cells per well. The total volume of 
complete media in the wells was 100 L. As previously described, to increase accuracy, a 
cell strainer was used to ensure they were in a single cell suspension before plating in the 
96-well plate. A repeating pipettor was used to plate cells. Cells were then allowed to 
incubate at 37°C and 5% CO2 atmosphere for 24 hours before the initial treatment to 
ensure 50-70% confluency in the experimental wells. There were triplicate wells for each 
treatment group. 
 
PARP INHIBITION DOSE RESPONSE ASSAY 
 For this assay, the PARP inhibitor 3-aminobenzamide was purchased from 
Sigma-Aldrich (St. Louis, MO). The powdered 3-AB was added directly to complete 
media (MEME + 10% FBS) and this solution was warmed to room temperature and 
manually stirred until dissolved. Complete media containing the PARP inhibitor 3-AB 
will be referred to as PARPi media for the following assay. Fresh PARPi media was 
made for each dose response assay, always with a final concentration of 33 µM 3-AB, 
which is the IC50 for 3-AB where half of PARP activity is inhibited (Curtin, 2007). 
 Temozolomide (TMZ) was prepared as previously described. The stock TMZ 
solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in PARPi 
 
 
media and subsequently used to create a serial dilution of TMZ in PARPi media in the 
following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M, and 200 M. 
Each solution was vortexed for at least 10 seconds and repeatedly mixed with a 
micropipettor to ensure homogenization. A control solution of 0.05% DMSO in PARPi 
complete media was also prepared.   
 Twenty-four hours after plating, the original complete media on the cells was 
removed using a multichannel micropipettor, being careful to not disturb the confluent 
cells. Next, media containing the different treatment concentrations of TMZ in PARPi 
complete media, the DMSO control in PARPi media, and a negative control of complete 
media was added to the cells. Cells were never without media for more than 15 minutes. 
The final volume of treatment solutions in the wells was 100 L. All plates were kept in 
an incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment time, with 
separate plates for each time point. 
 
PARP-1 SILENCING DOSE RESPONSE ASSAY 
For silencing treatment, PARP-1 siRNA was obtained from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA) and consisted of a pool of three human target-
specific 20-25 nucleotide siRNAs. To transfect the cells with the PARP-1 siRNA, 
INTERFERin™ (Polyplus, New York, NY) was used. For the silencing protocol, 0.17 L 
of 10 M PARP-1 siRNA was mixed by pipetting with 50 L MEME per well. Then 
0.75 L of INTERFERin™ per well was added to the PARP-1 siRNA solution.  These 
solutions were made as master mixes and the reagents were mixed by vortexing for 10 
seconds immediately after being combined. Then the PARP-1 siRNA treatment solution 
 
 
was incubated for 10 to 30 minutes at room temperature. During the incubation, the old 
media in the 96-well plate was removed and replaced with 125 L of new, complete 
media. Finally, 50 L of the siRNA treatment solution was added to each well by 
experimental group. The protocol from the manufacturer was used for all experiments, 
with the exception of a modification for a final concentration of 10 nM siRNA in each 
treatment well. 
Temozolomide (TMZ) was prepared as previously discussed. Briefly, the stock 
TMZ solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in 
complete media and subsequently used to create a serial dilution of TMZ in complete 
media in the following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M, 
and 200 M. Each solution was vortexed for at least 10 seconds and repeatedly mixed 
with a micropipettor to ensure homogenization. A control solution of 0.05% DMSO in 
complete media was also prepared.   
 At 24 hours after the silencing treatment was applied, the siRNA media on the 
cells was removed using a multichannel micropipettor, being careful to not disturb the 
confluent cells. Next, media containing the different treatment concentrations of TMZ in 
complete media, the DMSO control in media, and a negative control of complete media 
was added to the cells. Cells were never without media for more than 15 minutes. The 
final volume of treatment solutions in the wells was 100 L. All plates were kept in an 
incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment time, with 
separate plates for each time point. 
 
 
 
 
 
CELL VIABILITY ASSAY 
 As previously described, the CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, Madison, WI) was used to determine the number of viable cells after 
treatment. Luminescence was read using a Turner Biosystems Modulus® Microplate 
Reader (Sunnyvale, CA) at 24, 48, or 72 hours after the TMZ containing  treatment was 
applied, with triplicate wells for each experimental group within a cell line.  
 
STATISTICAL ANALYSIS 
 Luminescence values from the Cell-Titer Glo® protocol were converted to 
survival percentages relative to the untreated control survival values. The doses of 
temozolomide were transformed from micromolar values using the equation X=Log[X]. 
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to plot relative 
survival values against the transformed temozolomide doses to generate a dose response 
curves using a sigmoidal line of best fit. EC50 values were calculated from the best fit 
curves and analyzed using a repeated measures ANOVA with a Tukey post test. Graphs 
of EC50 values show the standard error of the mean (SEM). Significance was one asterisk 
(*) if p<0.05, two (**) if p<0.01 and three (***) if p<0.001. 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 After defining the dose response curves for all four cell lines at each of three time 
points (Chapter 3), the effect of adding 3-aminobenzamide, a PARP-1 inhibitor (PARPi) 
or the effect of silencing PARP-1 (PARPsil) with the established temozolomide treatment 
regimen was assessed. Figure 23 shows the results of a TMZ dose response curve with 
the addition of a constant concentration of PARPi (33 µM 3-AB). Analysis confirms the 
cell lines‟ curves showed significant differences at 72 hours (P<0.0001). Following 
PARP-1 silencing, the TMZ dose response best fit curves for all four cell lines were 
significantly different at 72 hours (P<0.0001) (Figure 24). In the PARP-1 silenced 
treatments there were six outliers excluded from the analysis, four in the LN-229 cell line 
and two in the T-98 cell line.  
 To perform a comparison on the efficacy of PARPi or PARP-1 silencing 
(PARPsil) on TMZ sensitivity, each cell line was analyzed separately. The U-87 cell line 
dose response curves at 72 hours for TMZ only, PARPi+TMZ, and PARPsil+TMZ are 
shown in Figure 25. The best fit curves for each treatment group showed significant 
differences (P=0.0189). Figure 26 shows a comparison of the EC50 values from the 72 
hour treatments for the U-87 cell line. An ANOVA showed significant differences 
(P=0.0012), between the TMZ only treatment (median EC50 of 859.5 µM TMZ) and the 
PARPi+TMZ treatment (median EC50 of 604.2 µM TMZ). However, the TMZ only 
treatment was not significantly different from the PARPsil+TMZ (median EC50 of 849.1 
 
 
µM TMZ). Finally, the two PARP treatments, inhibition of PARP (PARPi+TMZ) and 
silencing of PARP (PARPsil+TMZ) were highly significantly different from each other. 
 Analysis of the U-138 dose response curves to TMZ only, PARPi+TMZ, and 
PARPsil+TMZ treatments showed significantly different curves (P=0.0487)  (Figure 27). 
The EC50 values for each treatment were calculated from the curves and compared by 
ANOVA, which revealed there were significant differences between the treatments 
(P=0.0006) (Figure 28). The TMZ only treatment (median EC50 of 696.0 µM TMZ) 
showed a very highly significant difference from the PARPi+TMZ treatment (median 
EC50 of 502.1 µM TMZ). The TMZ only treatment was not significantly different than 
the PARPsil+TMZ (median EC50 of 655.5 µM TMZ). The two PARP treatments, 
PARPi+TMZ and PARPsil+TMZ were highly significantly different from each other in 
the U-138 cell line. 
 The dose response curves for the T-98 cell line were significantly different 
(P<0.0001) from each other (Figure 29). Two outliers were excluded from the curve 
analysis. In Figure 30, the EC50 values from each treatment group were compared, and 
ANOVA analysis showed significance (P=0.0381). The TMZ only treatment had a 
median EC50 of 1048.0, and was significantly different from the PARPsil+TMZ 
treatment, which had a median EC50 of 423.2 µM TMZ. The PARPi+TMZ treatment 
group was not significantly different from either of the other two treatments, and had a 
median EC50 of 771.3 µM TMZ.  
 Although the dose response curves generated for each treatment were not 
significantly different for the LN-229 cell line (Figure 31), an ANOVA performed on the 
extrapolated EC50 values showed significance (P=0.0003). Figure 32 shows a comparison 
 
 
of the EC50 values from each of the three groups, TMZ only, PARPi+TMZ, and 
PARPsil+TMZ treatments. The TMZ only treatment had a median EC50 value of 811.9 
µM TMZ and was very highly significantly different than the EC50 values for both PARP 
treatments. In the PARP inhibition (PARPi+TMZ), the median EC50 was 1179.0 µM 
TMZ, and was also very highly significantly different than the EC50 value in the PARP-1 
silenced treatment (PARPsil+TMZ), which had a median EC50 of 453.2 µM TMZ. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 Dose response assays to TMZ with the addition of a constant dose of the PARP 
inhibitor (PARPi) 3-aminobenzamide were performed for each cell line at three different 
time points: 24, 48, and 72 hours.  Dose dependent response curves were characterized in 
all four cell lines (LN-229, T-98, U-87, and U-138) at the 72 hour time point (Figure 23). 
Because the cell lines are from four different tumors it was expected that the dose 
response curves would vary between cell lines. This is what was observed when 
PARPi+TMZ responses were compared (Figure 23). 
Next, dose response assays to TMZ with the addition of a constant PARP-1 
silencing were performed for each cell line at three different time points: 24, 48, and 72 
hours.  Dose dependent response curves to this treatment were characterized in all four 
cell lines (LN-229, T-98, U-87, and U-138) at the 72 hour time point (Figure 24). Again, 
because the cell lines are from four different tumors, the alternate hypothesis was that the 
curves would be different for each cell line and the null hypothesis stated the cell lines 
would have the same response. The null hypothesis was rejected, because the 72 hour 
curves from PARPsil+TMZ treatment were significantly different from each other, as 
expected (Figure 24). 
The curves for treatment with the PARP inhibitor 3-aminobenzamide 
(PARPi+TMZ) and addition of PARP-1 siRNA silencing (PARPsil+TMZ) were 
compared to the TMZ only dose response at 72 hours for each cell line (Figures 25 
through 32). The alternate hypothesis for this comparison was that each cell line would 
have different curves for each treatment, in contrast to the null hypothesis which stated 
 
 
each treatment would show the same curve. Excluding the LN-229 cell line, the curves 
for the three treatments were significantly different for the remaining cell lines at the 72 
hour time point and the null hypothesis was rejected. It was expected that the cell lines 
would respond differently to TMZ only, PARPi+TMZ, and PARPsil+TMZ treatments. 
The EC50 values for each of the experimental treatments were calculated from the 
dose response curves and compared by cell line to the TMZ only control treatment. In the 
U-87 and U-138 cell lines, the PARPi+TMZ treatment showed the most significant 
decrease in the EC50 value or highest increase in sensitivity to TMZ (Figures 26 and 28). 
Likewise, there was a slight decrease in EC50 value for the PARPsil+TMZ treatment for 
both cell lines, but it was not significantly different from the TMZ only control. In both 
U-87 and U-138 cell lines, the PARPi+TMZ treatment EC50 value was significantly 
lower than the PARPsil+TMZ treatment. Thus, the addition of the PARP inhibitor 
showed the highest increase in sensitivity to TMZ in the U-87 and U-138 cell lines, and it 
was expected that manipulating PARP would show significant differences in the response 
to TMZ.  
In the other two cell lines, T-98 and LN-229, the PARPsil resulted in the highest 
increase in sensitivity to TMZ (Figures 30 and 32). For the T-98 cell line, the 
PARPi+TMZ treatment showed a decreased EC50, but was not significant. However, the 
PARPsil+TMZ showed a significantly decreased EC50 value compared to the TMZ only 
control. This indicates an increased sensitivity to TMZ in the silencing treatment for the 
T-98 cell line (Figure 30). Accordingly, the LN-229 cell line showed a significantly 
decreased EC50 value when the TMZ only control was compared to the PARPsil+TMZ 
treatment, thus an increase in TMZ sensitivity (Figure 32). Unlike the other cell lines the 
 
 
LN-229 cell line treated with PARPi+TMZ had a significantly increased EC50 compared 
to the TMZ only control, showing decreased TMZ sensitivity. This was unexpected, 
however other differences in sensitivity to TMZ when PARP was manipulated were 
expected. 
 In conclusion, for two cell lines (U-87 and U-138), the addition of the PARP 
inhibitor 3-aminobenzamide at a constant dose to TMZ treatment caused a significant 
increase in sensitivity to TMZ (Figures 26 and 28). For the other two cell lines (T-98 and 
LN-229), when PARP-1 was silenced with TMZ treatment, the TMZ sensitivity increased 
significantly (Figures 30 and 21). Finally, with the exception of LN-229 PARPi+TMZ 
treatment, the EC50 values decreased when PARP was manipulated by the addition of 
either a PARP inhibitor or PARP-1 siRNA to TMZ treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FIVE: COMBINATION STUDIES 
 
 
 
 
 Although TMZ can be used alone as monotherapy, or in addition to irradiation 
therapy in the treatment of GBM, there are several indications that combination therapies 
may be more effective in decreasing initial or acquired resistance to TMZ. As previously 
discussed, the antitumor activity of the O
6 –methylguanine position can be attenuated by 
the presence of MGMT (Hegi et al., 2005). In addition, the participation of PARP-1 in 
DNA damage repair pathways such as BER, contributes to a cancer cell‟s resistance to 
therapy with DNA damaging agents like TMZ (Villano et al., 2009). Therefore, strategies 
to target multiple resistance mediators may be an appropriate therapy for GBM.  
 
STRATEGIES TO DECREASE RESISTANCE 
 As discussed, the cytotoxicity of TMZ is mainly mediated by the methyl adduct at 
the O
6 
position, whereby unsuccessful cycles of MMR cause irreparable DSBs in the 
DNA. When MGMT is present it is able to restore the integrity of the O
6 
position and 
thus, resistance occurs. While there have been several studies that have investigated the 
use of structural analogs such as O
6 –Benzylguanine (O6 –BG) to deplete the cell‟s 
MGMT suicide enzymes, it appears this may only be a transient inhibition and some 
increases in systemic toxicity were found (Hegi et al., 2008). With the advent of delivery 
agents that could support human use of siRNA, specific targeting of MGMT within a 
limited area surrounding the tumor bed may be a suitable alternative to using additional 
chemotherapy drugs. 
 
 
 Additionally, the other sites where TMZ adds methyl adducts, N
7
-methylguanine, 
N
3
-methyladenine, comprise most (~80%) of the damage done to DNA (Villano et al., 
2009).  These methylpurines are thought to be repaired through the BER pathway, and do 
not contribute substantially to the antitumor activity of TMZ. However, studies have 
shown that following TMZ treatment and PARP inhibition, these methylpurines persist 
and there are increased levels of SSBs and DSBs in the DNA (Heacock et al., 2010). In 
this way, PARP inhibition can attenuate resistance to TMZ, even in MMR-deficient cells, 
as this has been shown in a glioma xenograft (Cheng et al., 2005). By restraining the 
BER pathway, PARP inhibition could be a beneficial adjuvant to several types of 
chemotherapy drugs.  
 Although there are several PARP inhibitors entering and currently being tested in 
clinical trials, the addition of drugs to a strenuous chemotherapy and/or radiotherapy 
regimen could result in multiple off target effects. Such as the case with the MGMT 
inhibitor O
6
-BG, where quelling an enzyme that is responsible for reversing DNA 
damage in normal cells, which can cause significant side effects, such as hematologic 
toxicity (Hegi et al., 2008). However, as previously mentioned, by targeting PARP-1 (and 
MGMT) using siRNA could be a fitting alternative to combining several types of 
chemotherapy drugs.  
 
SILENCING IN HUMANS 
 Progress toward the in vivo use of siRNAs has been exciting for multiple models 
of disease. The first human clinical trial of synthetic siRNA was launched in 2004 in 
patients suffering from blinding choroidal neovascularization and has been followed by 
 
 
several additional clinical studies (Davis et al., 2010). The first clinical trial using a 
targeted nanoparticle-delivery system in patients with solid cancers was conducted by 
Davis et al. (Clinical Trial Registration Number NCT00689065). The novel delivery 
system for the specific siRNAs was composed of a linear polymer conjugated to a 
targeting ligand (a human transferrin protein ligand), and an additional hydrophilic 
polyethylene glycol (PEG) polymer for stability in biological fluids. In this case, the 
targeting ligand was specific for tumor cells overexpressing the transferrin receptor. 
Conclusions from the phase I study indicated that RNAi can be stimulated in humans 
using synthetic siRNA delivered with targeted nanoparticles (Davis et al., 2010). 
 There are several advantages to siRNA and the delivery system outlined above 
(Davis, 2009). First, siRNA can be designed for any protein and can elicit an RNA 
interference mechanism in humans. Second, the linear polymer is able to wrap naked 
siRNA into nanoparticles based on the electrochemical attractions of these two molecules 
and are small enough (50 to 70 nm) to be endocytosed into cells. Third, the stabilizing 
polymer can be conjugated to a targeting ligand to bind specific cell surface receptors 
(e.g. those that are overexpressed or mutated in certain cancers). Fourth, once 
endocytosed, the siRNA is able to be released during the acidification of the endosome, 
which initiates the dissembly of the nanoparticle and escape from the endosome. These 
advantages came together in the development of CALAA-01, a two-vial formulation of 
three components: the delivery components of a linear polymer and a PEG polymer with 
the targeting ligand in the first vial, and the second vial containing the siRNA (Davis, 
2009). This two vial delivery system, when combined, self-assembles into nanoparticles 
and can be given via intravenous administration and was shown to localize in the targeted 
 
 
area (Davis et al., 2010). These studies are promising and may soon lead to additional 
targeted therapies.  
 
AIMS 
The literature indicates a strong correlation between MGMT activity and 
increased resistance to TMZ. Multiple lines of reasoning support PARP inhibition 
lending to increased sensitivity to TMZ. This study was designed to test cell response to 
MGMT and PARP-1 inhibition in combination with TMZ treatment. The primary goal 
was to compare the differences between response to 1) single agent TMZ, 2) MGMT 
silencing with TMZ treatment, 3) double silencing using siRNA to MGMT and PARP-1 
with concomitant TMZ, and 4) MGMT silencing with PARP-1 inhibition via 3-AB and 
concomitant TMZ treatment in GBM cell lines. The secondary goal of this research was 
to compare the differences between responses to all types of treatments investigated in 
this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
 
 
 
CELL CULTURE 
 The four human glioma cell lines obtained from the ATCC were cultured as 
previously described. For PARP-1 inhibition (PARPi) dose response assays, cells were 
transferred to a 96-well plate and plated at 5,000 cells per well. The total volume of 
complete media in the wells was 100 L. As described, to increase accuracy, a cell 
strainer was used to ensure a single cell suspension before plating in the 96-well plate. A 
repeating pipettor was used to plate cells. Cells were allowed to incubate at 37°C and 5% 
CO2 atmosphere for 24 hours before the initial treatment to ensure 50-70% confluency 
within the experimental wells. There were triplicate wells for each treatment group. 
 
COMBINATION DOSE RESPONSE ASSAY 
For silencing treatment, MGMT siRNA was obtained from Applied 
Biosystems/Ambion (Austin, TX) and diluted to a 10 M working solution. To transfect 
the cells with the MGMT siRNA, INTERFERin™ (Polyplus, New York, NY) was used. 
For the silencing protocol, 0.17 L of 10 M MGMT siRNA was mixed by pipetting 
with 50 L MEME, per well. Then, 0.75 L of INTERFERin™, per well, was added to 
the PARP-1 siRNA solution.  These solutions were made as master mixes and the 
reagents were mixed by vortexing for 10 seconds immediately after being combined. 
Following this, the MGMT siRNA treatment solution was incubated for 10 to 30 minutes 
at room temperature. During the incubation, the old media in the 96-well plate was 
removed and replaced with 125 L of new, complete media. Finally, 50 L of the siRNA 
 
 
treatment solution was added to each well by experimental group. The protocol from the 
manufacturer was used for all experiments, with the exception of a modification for a 
final concentration of 10 nM siRNA in each treatment well.   
As previously described, the PARP inhibitor, 3-aminobenzamide, was purchased 
from Sigma-Aldrich (St. Louis, MO). Fresh PARPi media with a final concentration of 
33 µM 3-AB was used. Temozolomide (TMZ) was prepared as previously discussed. The 
stock TMZ solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in 
PARPi media and subsequently used to create a serial dilution of TMZ in PARPi media 
in the following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M, and 200 
M. Each solution was vortexed for at least 10 seconds and repeatedly mixed with a 
micropipettor to ensure homogenization. A control solution of 0.05% DMSO in PARPi 
complete media was also prepared.   
 At 24 hours after treatment, the siRNA containing media on the cells was 
removed using a multichannel micropipettor and care was taken not to disturb the 
confluent cells. Next, media containing the different treatment concentrations of TMZ in 
PARPi complete media, the DMSO control in PARPi media, and a negative control of 
complete media was added to the cells. Cells were never without media for more than 15 
minutes. The final volume of treatment solutions in the wells was 100 L. All plates were 
kept in an incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment 
time, with separate plates for each time point. 
 
 
 
 
 
COMBINATION SILENCING DOSE RESPONSE ASSAY 
For combination silencing treatment, PARP-1 siRNA (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) and MGMT siRNA (Applied Biosystems/Ambion, Austin, TX) 
were diluted to a 10 M working solution. To transfect the cells with both siRNAs, 
INTERFERin™ (Polyplus, New York, NY) was used. To keep the final concentration of 
siRNA at 10 nM in each treatment well, 0.85 L of 10 M PARP-1 siRNA and 0.85 L 
of 10 M MGMT siRNA, per well,  was mixed by pipetting with 50 L MEME. Then, 
0.75 L of INTERFERin™, per well, was added to the combined siRNA solution.  These 
solutions were made as master mixes and the reagents were vortexed for 10 seconds 
immediately after being combined. Then the siRNA treatment solution was incubated for 
10 to 30 minutes at room temperature. During the incubation, the old media in the 96-
well plate was removed and replaced with 125 L of new, complete media. Finally, 50 
L of the siRNA treatment solution was added to each well by experimental group.  
Temozolomide (TMZ) was prepared as previously discussed. Briefly, the stock 
TMZ solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in 
complete media and subsequently used to create a serial dilution of TMZ in complete 
media in the following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M, 
and 200 M. Each solution was vortexed for at least 10 seconds and repeatedly mixed 
with a micropipettor to ensure homogenization. A control solution of 0.05% DMSO in 
complete media was also prepared.   
 At 24 hours after the silencing treatment was applied, the siRNA media on the 
cells was removed using a multichannel micropipettor, and care was taken not to disturb 
the confluent cells. Next, media containing the different treatment concentrations of TMZ 
 
 
in complete media, the DMSO control in media, and a negative control of complete 
media was added to the cells. Cells were never without media for more than 15 minutes. 
The final volume of treatment solutions in the wells was 100 L. All plates were kept in 
an incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment time, with 
separate plates for each time point. 
 
CELL VIABILITY ASSAY 
 As previously described, the CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, Madison, WI) was used to determine the number of viable cells after 
treatment. Finally, luminescence was read using a Turner Biosystems Modulus® 
Microplate Reader (Sunnyvale, CA) at 24, 48, or 72 hours after the TMZ containing  
treatment was applied, with triplicate wells for each experimental group within a cell line.  
 
STATISTICAL ANALYSIS 
 Luminescence values from the Cell-Titer Glo® protocol were converted to 
survival percentages relative to the untreated control survival values. The doses of 
temozolomide were transformed from micromolar values using the equation X=Log[X]. 
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to plot relative 
survival values against the transformed temozolomide doses to generate a dose response 
curves using a sigmoidal line of best fit. EC50 values were calculated from the best fit 
curves and analyzed using a repeated measures ANOVA with a Tukey post test. Graphs 
of EC50 values show the standard error of the mean (SEM). Significance was one asterisk 
(*) if p<0.05, two (**) if p<0.01 and three (***) if p<0.001. 
 
 
RESULTS 
 
 
 
 
 In order to characterize the changes in TMZ sensitivity between PARP 
manipulation and other known GBM targets, the effect of silencing MGMT in several 
combination treatments was assessed. Figure 33 shows curves generated from a 72 hour 
dose response curve where MGMT was silenced (MGMTsil) in addition to TMZ 
treatment. Analysis showed the curves for the four cell lines were significantly different 
from one another (P=0.0005). During the analysis, no outliers were found. In addition, 
the effect of silencing MGMT and PARP-1 at the same time (BOTHsil) to TMZ 
treatment was assessed at 72 hours, as shown in Figure 34. Likewise, the curves for each 
of the four cell lines were found to be significantly different from one another 
(P<0.0001). In this analysis, one outlier (U-138) was excluded.  
 Additionally, the effect of PARP inhibition in combination with MGMT silencing 
when added to TMZ treatment was assessed. For this treatment 
(PARPi+MGMTsil+TMZ), a constant dose of 33 µM 3-aminobenzamide (PARPi) was 
added to MGMT silencing. Then, increased doses of TMZ were administered as 
previously described. The resulting curves for each of the four cell lines were 
significantly different from each other (P=0.0051) (Figures 33, 34, and 35). There were 
also no outliers found during this analysis.  
 Finally, each cell line was analyzed separately to determine changes in TMZ 
sensitivity between the five different treatments. Briefly, for these analyses, the EC50 
values were extrapolated from the 72 hour dose response curves for the control (TMZ 
only) and five treatment groups. The five treatment groups are as follows: PARPi+TMZ 
 
 
(the addition of a constant dose of 33 µM 3-aminobenzamide to the different 
concentrations of TMZ), PARPsil+TMZ (constant silencing of PARP-1 in addition to 
TMZ), MGMTsil+TMZ (constant silencing of MGMT in addition to TMZ treatment), 
BOTHsil+TMZ (silencing of PARP-1 and MGMT at the same time in addition to TMZ 
treatment), and lastly, PARPi+MGMTsil+TMZ (the addition of a PARP inhibitor as 
previously described, constant MGMT silencing, and TMZ treatment). 
 In the treatment comparison for the U-87 cell line shown in Figure 37, there were 
significant differences (P<0.0001). When compared to the control TMZ only treatment, 
the PARPi+MGMTsil+TMZ treatment showed a very highly significant decrease in EC50 
value, followed closely by the PARPi+TMZ treatment (TMZ only median EC50 was 
859.5 versus 599.2 and 604.2, respectively). The PARPi+TMZ and 
PARPi+MGMTsil+TMZ treatments were not significantly different from each other. 
However, the BOTHsil+TMZ treatment also showed a highly significantly decreased 
EC50, with a median EC50 739.4 µM TMZ when compared to the TMZ only control. 
Moreover, the BOTHsil+TMZ treatment was highly significantly different than the 
PARPi+TMZ and PARPi+MGMTsil+TMZ treatments, showing an increased EC50 value. 
The PARPsil+TMZ treatment was not significantly different than the TMZ only control. 
Interestingly, the MGMTsil+TMZ treatment showed a very highly significantly increased 
EC50 value (median 1027.0 µM TMZ).  
 The U-138 cell line treatment comparison showed two treatments with 
significantly decreased EC50 values compared to the TMZ only control (P=0.0009) 
(Figure 37). The PARPi+TMZ treatment showed the most significant decrease in EC50 
value (median was 502.1 versus 696.0 µM TMZ for the TMZ only control). Although the 
 
 
PARPsil and MGMTsil treatments did not show significant differences from the TMZ 
only control, the BOTHsil treatment EC50 was significantly lower, with a median EC50 of 
546.5 µM TMZ. Interestingly, the PARPi+MGMTsil+TMZ treatment showed a highly 
significant increased EC50 (median of 901.5 µM TMZ) compared to the TMZ only 
control. The difference between the PARPi+TMZ and BOTHsil+TMZ treatments was not 
significant. However, the PARPi+TMZ treatment was significantly different than the 
PARPsil treatment and the MGMTsil treatment. Accordingly, the 
PARPi+MGMTsil+TMZ treatment was very highly significantly different than the other 
treatment groups. 
 In the treatment comparison of the T-98 cell line, only two treatments were 
significantly different, P=0.0040, than the control of TMZ only (Figure 38). The 
PARPsil+TMZ showed the most significantly decreased EC50 value compared to the 
TMZ only treatment (median EC50 values of 423.2 versus 1048.0 µM TMZ, 
respectively). Compared to the TMZ only control, the PARPi+MGMTsil+TMZ treatment 
showed the next most significantly decreased EC50 value, with a median EC50 of 556.0 
µM TMZ. The other three treatments were not significantly different from the control of 
TMZ only. Additionally, the only other significant difference was between the 
PARPsil+TMZ and the MGMTsil+TMZ treatment groups, with the median EC50 for 
MGMTsil+TMZ at 958.3 µM TMZ. 
 The LN-229 cell line had significant difference between the TMZ only control 
and all other treatment groups (P<0.0001) (Figure 39). The PARPsil+TMZ and 
PARPi+MGMTsil+TMZ treatment groups had very highly significantly decreased EC50 
values, with median EC50 values of 453.2 and 574.1 µM TMZ, respectively, compared to 
 
 
the TMZ only control median EC50 of 811.9 µM TMZ. These two treatment groups were 
also significantly different from one another. Interestingly, the other three treatment 
groups showed significantly increased EC50 values compared to the control. The 
PARPi+TMZ and BOTHsil+TMZ showed the highest significantly increased EC50 values 
(median EC50 values of 1179.0 and 1139.0 µM TMZ, respectively), followed by the 
MGMTsil+TMZ treatment group, with a median EC50 of 1022.0 µM TMZ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 Dose response assays to TMZ with the addition of constant MGMT silencing 
were performed for each cell line at three different time points: 24, 48, and 72 hours.  
Dose dependent response curves were characterized in all four cell lines (LN-229, T-98, 
U-87, and U-138) at the 72 hour time point (Figure 33). Because the cell lines are from 
four different tumors, the alternate hypothesis was that the curves would be different for 
each cell line and the null hypothesis stated the cell lines would have the same response. 
The null hypothesis was rejected, as the 72 hour curves from MGMTsil+TMZ treatment 
were significantly different from each other, which was the expected result. 
Next, dose response assays to TMZ with the addition of constant MGMT and 
PARP-1 silencing (BOTHsil) was performed for each cell line at three different time 
points: 24, 48, and 72 hours.  Dose dependent response curves to this treatment were 
characterized in all four cell lines (LN-229, T-98, U-87, and U-138) at the 72 hour time 
point (Figure 34). Again, because the cell lines are from four different tumors, the 
alternate hypothesis was that the curves would be different for each cell line and the null 
hypothesis stated the cell lines would have the same response. The null hypothesis was 
rejected, and as expected the 72 hour curves from BOTHsil+TMZ treatment were 
significantly different from each other. 
The final treatment, the addition of a constant dose of the PARP inhibitor 3-
aminobenzamide and constant MGMT silencing (PARPi+MGMTsil+TMZ) to TMZ dose 
response assays was performed in each of the cell lines. Dose dependent response curves 
to this treatment were characterized in all four cell lines (LN-229, T-98, U-87, and U-
 
 
138) at the 72 hour time point (Figure 35). Accordingly, because the cell lines are from 
four different tumors, the alternate hypothesis was that the curves would be different for 
each cell line and the null hypothesis stated the cell lines would have the same response. 
The null hypothesis was rejected, as the 72 hour curves from PARPi+MGMTsil+TMZ 
treatment were significantly different from each other. This was the expected result for 
this experiment. 
 The final analysis for each cell line was comparing the calculated EC50 values 
from all five treatments to the TMZ only control (Figures 36, 37, 38, and 39). In the U-87 
cell line, it was previously shown that the addition of PARPi to TMZ treatment 
significantly increased TMZ sensitivity; but adding PARPsil to TMZ did not significantly 
increase sensitivity (Figure 26). Silencing MGMT did not result in increased sensitivity 
to TMZ. However, when MGMT and PARP-1 were silenced concomitantly, there was a 
significant increase in sensitivity to TMZ. Nonetheless, the most significantly decreased 
EC50 values were for the PARPi+TMZ and the PARPi+MGMTsil+TMZ treatments, 
corresponding to the highest increases in TMZ sensitivity (Figure 36).  
 When the U-138 cell line was analyzed there were some unexpected results 
(Figure 37). As previously shown, the PARPi+TMZ treatment showed a significant 
decrease in EC50, thus an increased sensitivity to TMZ (Figure 28). Neither PARPsil nor 
MGMTsil addition to TMZ treatments showed a significant difference in EC50 values 
when compared to the TMZ only control. When both targets were silenced (BOTHsil), 
there was a significant decrease in EC50 value, which was not significantly different from 
the PARPi+TMZ treatment, but nevertheless showed an increased sensitivity to TMZ 
when both targets were silenced. Although the PARPi+TMZ treatment had already 
 
 
shown a significant decrease in EC50, and the MGMTsil+TMZ showed an insignificant 
decrease, when combined in the PARPi+MGMTsil+TMZ treatment, the EC50 value 
significantly increased, displaying a decreased sensitivity to TMZ, which was unexpected 
(Figure 37). 
 The T-98 cell line showed high variability in the TMZ only result, and had only 
shown a significant increase in sensitivity to TMZ in the PARPsil+TMZ treatment group; 
although the PARPi+TMZ treatment did show a decreased EC50 value (Figure 30). When 
silenced alone, MGMTsil+TMZ did not show a significant decrease in EC50, but when 
silenced concomitantly with PARP-1 (BOTHsil), there was a larger, though insignificant, 
decrease in EC50. This was surprising because the PARPsil+TMZ shows the largest 
significant decrease in EC50, or highest sensitivity to TMZ. Although PARP inhibition 
alone in conjunction with TMZ did not produce a significant increase in sensitivity to 
TMZ, when MGMT silencing was added (PARPi+MGMTsil+TMZ), TMZ was 
significantly increased. As expected, none of the treatments showed an increase in EC50 
values compared to the TMZ only control (Figure 38).  
 When the LN-229 cell line was analyzed, there were several unexpected results 
(Figure 39). As previously shown, the LN-229 cell line showed the only significant 
increase in EC50 value when PARP was manipulated, in the PARPi+TMZ treatment 
group (Figure 32). Interestingly, when PARP inhibition was combined with MGMT 
silencing (PARPi+MGMTsil+TMZ), the sensitivity to TMZ was significantly increased, 
which was unexpected. However, the PARPsil+TMZ showed a significant decrease in 
EC50 value compared to the PARPi+MGMTsil+TMZ, so it was still the most effective 
treatment at increasing sensitivity to TMZ in the LN-229 cell line. Unexpectedly, 
 
 
although there were significant decreases in EC50 when PARP-1 was silenced, when 
PARP-1 silencing was combined with MGMT (BOTHsil) there was a significant increase 
in EC50. Likewise, there was a significant increase in EC50 when only MGMT was 
silenced (MGMTsil+TMZ). However, when PARP was inhibited with MGMT silencing 
(PARPi+MGMTsil+TMZ), the EC50 was significantly decreased. Thus, the only 
treatments that significantly increased TMZ sensitivity were PARPsil+TMZ and 
PARPi+MGMTsil+TMZ and the other three treatments significantly decreased 
sensitivity to TMZ (Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY & CONCLUSIONS 
 
 
 
SILENCING WITH A PEI-BASED PROTOCOL 
 
The primary aim of this thesis was to investigate methods for increasing 
temozolomide sensitivity in glioblastoma multiforme. Once the presence of GAPDH, an 
endogenous control, MGMT, and PARP-1 mRNA was confirmed (Figure 1), clinically 
relevant silencing methods were employed to determine if MGMT and PARP-1 could be 
knocked down in the glioblastoma cancer cell lines (Figures 2 through 8). Previous work 
has indicated that MGMT and PARP-1 are able to be knocked down using siRNA (Aneja 
et al., 2011; Hegi et al., 2005). Furthermore, the polyethylenimine-based protocol 
INTERFERin™ has been shown to deliver bioactive siRNA into cells (Alshamsan et al., 
2009).Thus, it was expected this protocol would be able to reduce gene expression in the 
human glioma cell lines, and this was true when one or both MGMT and PARP-1 
siRNAs were applied at the same time using the polyethylenimine-based protocol. 
Moreover, it was determined that the knockdown of MGMT and PARP-1 could be 
sustained in the cells for 72 hours (Figures 3 and 6). Although there has been a large 
amount of research on both MGMT and PARP-1 as targets in cancer therapy, it currently 
appears studies with simultaneous silencing of MGMT and PARP-1 have not been 
published (Hegi et al., 2008; Horton et al., 2009). 
 
RESPONSE TO TEMOZOLOMIDE 
 
  Next, while TMZ has been established as the standard of care for GBM, in order 
to do additional treatment studies it was necessary to establish a consistent method for 
 
 
creating TMZ dose response curves in the four cell lines of interest (Stupp et al., 2005). 
Dose dependent TMZ responses were observed and characterized in all four cell lines at 
three different time points (Figures 9 through 22). Although there was a larger amount of 
variability in the T-98 cell line at 72 hours (Figure 21), the procedure for generating the 
curves was very consistent between cell lines and is able to be replicated (Figures 9 
through 22). Furthermore, the effective concentration (EC50) of TMZ that killed 50% of 
the cells for each cell line was calculated from the dose response curves and at each time 
point (Figures 17 through 22).  
 The cell lines are from four different tumors, thus, it was expected the response to 
TMZ would be different in each line when the EC50 values were compared. Furthermore, 
a variable response to TMZ between the different cell lines had been previously observed 
(Davis, 2008). The variability between cell lines was true for the 24 and 48 hour time 
points, but not for the 72 hour time point (Figures 17, 18 and 19). When the EC50 values 
were analyzed within cell lines by time point, some patterns appear (Figures 19, 20, 21, 
and 22). The U-138 EC50 values significantly decrease over the three time points (Figure 
20). This pattern also appears in the T-98 cell line; however, the differences were not 
significant, presumably because of the large variability in the 72 hour EC50 value (Figure 
21). The EC50 values for the LN-229 cell line significantly decrease from the 24 to 48 
hour time points, however, significantly increase from the 48 to the 72 hour time point 
(Figure 22). But, the values at 24 and 72 hours for the LN-229 cell line were not 
significantly different from one another. The opposite pattern appears in the U-87 cell 
line, where the 24 hour EC50 value was significantly lower than the 48 and 72 hour values 
 
 
(Figure19). Although it appears that the EC50 value decreases from 48 to 72 hours, it was 
not significantly different.  
 Generating dose response curves for all of the cell lines at three different time 
points was successful (Figures 9 through 15). When compared to results from a previous 
study, the EC50 values from these experiments were higher for three of the four cell lines 
(Davis, 2008). For the U-87, T-98, and LN-229 cell lines, the EC50 was an average of 
442.0 µM higher (range of 414.67 to 469.73 µM) than previously reported, but the U-138 
cell line was 258.6 µM lower than previously reported (Davis, 2008). For most of the cell 
lines, the 72 hour EC50 value was lower than the 48 hour value (excepting the LN-229 
cell line, where the 72 hour value was similar to the 24 hour value). Since this pattern 
appeared to be the most constant, the manipulations of PARP-1 and MGMT were 
analyzed at 72 hours. Moreover, previous work indicated 72 hours of TMZ exposure was 
optimal to induce cell death (Davis, 2008). Finally, the procedure for conducting TMZ 
dose response curves appears to be sufficiently established and is replicable as shown for 
the twelve experiments in Figures 9 through 22.  
 Considering the expression of MGMT as previously reported (Davis, 2008), the 
results found in this study agree with the role of MGMT as a TMZ resistance factor in 
GBM (Hegi et al., 2008; Liu et al., 2009b). The T-98 cell line, which has the highest 
MGMT expression relative to the other three cell lines, has the highest EC50 value 
indicating it was the least sensitive to TMZ treatment (Figures 16, 17, and 18). In the U-
138 cell line, which has the next highest relative MGMT expression, had the next highest 
EC50 value at 24 hours (Figure 16), however by 72 hours the EC50 had decreased 
significantly (Figure 20). The U-87 cell line, which had minimal MGMT expression 
 
 
relative to the other cell lines had the lowest EC50 at 24 hours indicated the most 
sensitivity to TMZ (Figure 16), but by 72 hours had an EC50 value higher than U-138 
cells (Figure 18).  The LN-229 cell line had the lowest relative amount of MGMT 
expression, and was the most sensitive of the cell lines to TMZ at 48 hours (Figure 17) 
but had a higher EC50 than the U-138 cell line at 72 hours (Figure 18). The agreement 
between MGMT expression and TMZ showed similar variability in previous work to the 
results presented herein (Davis, 2008). However, MGMT expression is not the only 
determinant in sensitivity to TMZ, and considering the role that MMR plays in initiating 
the cytotoxic SSBs in DNA, the literature indicates the functional status of these 
additional pathways plays a significant role (Johannessen et al., 2008; Villano et al., 
2009). 
 
PARP MANIPULATION 
 
Because inhibition of PARP-1 has been associated with increased sensitivity to 
chemotherapy agents like TMZ, the effect of PARP-1 inhibition and PARP-1 siRNA 
treatment were explored (Curtin, 2005; Mangerich and Burkle, 2011). Dose dependent 
TMZ responses with the addition of either a PARP inhibitor (33 µM 3-aminobenzamide) 
or PARP-1 siRNA treatment were observed and characterized in all four cell lines at the 
72 hour time point (Figures 23 and 24). The curves for treatment with the PARP inhibitor 
3-aminobenzamide (PARPi+TMZ) and addition of PARP-1 siRNA silencing 
(PARPsil+TMZ) were compared to the TMZ only dose response at 72 hours for each cell 
line (Figures 25, 27, 29, and 31). Based on the functions of PARP-1 in BER, and 
specifically in repairing damage induced by alkylating agents, it was expected the 
 
 
addition of PARP-1 siRNA or the inhibitor 3-AB would cause the response to TMZ to 
change from the TMZ only baseline (Heacock et al., 2010; Liu et al., 2009a). Excluding 
the LN-229 cell line, the curves for the three treatments were significantly different for 
the remaining cell lines at the 72 hour time point (Figures 23 and 24), as expected. 
Considering the previous discussion of the single agent TMZ response results, it 
remained expected that the cell lines should have different responses from one another 
because they are from different tumors, in addition to variations in the response between 
different treatments for a cell line (Chen et al., 2007; Hegi et al., 2005). 
The effective concentration (EC50) of TMZ that killed 50% of the cells for each 
cell line was calculated from the dose response curves for the PARP manipulation 
treatments (Figures 26, 28, 30, and 32). The expectation was that the response to PARP 
manipulation would be an increase in TMZ sensitivity, thus a decrease in the EC50 from 
the 72 hour TMZ only response (Tentori et al., 2006; Tentori and Graziani, 2009). 
Accordingly, the addition of the PARP inhibitor showed the highest increase in 
sensitivity to TMZ in the U-87 and U-138 cell lines (Figures 26 and 28). In the other two 
cell lines, T-98 and LN-229, the PARP-1 siRNA treatment showed the highest increase in 
sensitivity to TMZ (Figures 30 and 32). With the exception of the LN-229 PARPi+TMZ 
treatment, the EC50 values decreased when PARP was manipulated by the addition of 
either a PARP inhibitor or PARP-1 siRNA to TMZ treatment.  
The PARP inhibitor used for this assay was 3-aminobenzamide, which mimics the 
normal substrate of PARP, NAD+ (Curtin, 2005; D'Amours et al., 1999; Ratnam and 
Low, 2007). Although suitable for experimental applications, clinical inhibitors have 
increased specificity and other properties making them more tolerable in a clinical setting 
 
 
(Ratnam and Low, 2007). Additionally, in this assay 3-AB was used at a single 
concentration of 33 µM, which is the IC50, or dose where half of the PARP activity is 
inhibited and we assumed this IC50 was the same for our cell lines (Jagtap and Szabo, 
2005). Based on the silencing studies of PARP-1 silencing with the PEI-based protocol, 
the levels of PARP-1 were drastically reduced (Figures 5, 6, and 8) after siRNA 
treatment. It would be pertinent to test the amount of PARP activity after treatment with 
3-AB or PARP-1 siRNA, however, without that information, it is still likely that PARP-1 
siRNA would have had a greater effect than 3-AB because of its specificity for the 
PARP-1 mRNA. This was true in the T-98 and LN-229 cell lines (Figures 30 and 32), but 
not in the U-87 and U-138 cell lines (Figures 26 and 28). Some research suggests 
glioblastoma cells can modulate the transport of drugs and other extracellular factors 
across their membrane and use this to mediate resistance to temozolomide (Le Calve et 
al., 2010). This may explain some of the differences in response to PARP manipulation 
treatment between these cell lines, as well as some of the unexpected results in the 
combination treatments discussed later. 
 
COMBINED MANIPULATION 
 
The literature shows a strong correlation between MGMT activity and increased 
resistance to TMZ, so silencing studies were done to examine the effect of MGMT 
siRNA and combination MGMT and PARP-1 siRNA (BOTHsil) treatments (Hegi et al., 
2005; Hegi et al., 2008). For both of these treatments, dose dependent response curves 
were characterized in all four cell lines at 72 hours (Figures 33, 34, and 35). Again, 
because the cell lines were derived from different tumors, it was expected that the 
 
 
response would be different to each treatment for every cell line. This was confirmed for 
the MGMTsil treatment as well as the BOTHsil treatment. Moreover, it was expected 
MGMTsil treatment would increase sensitivity in the cell lines based on previous work 
(Davis, 2008). In light of the functions of MGMT and PARP-1 and studies examining 
their relationship, it was expected this treatment would increase sensitivity to TMZ more 
than either MGMTsil or PARPsil would (Hegi et al., 2008; Liu et al., 2009b; 
Madhusudan and Middleton, 2005). 
In the two cell lines that had previously responded to PARP-1 silencing treatment 
(T-98 and LN-229; Figures 30 and 32), sensitivity to TMZ did not increase for MGMTsil 
or BOTHsil (Figures 38 and 39). In the T-98 cell line, PARPsil treatment remained more 
effective than either of the other silencing treatments. In fact, for both MGMTsil and 
BOTHsil treatments in the LN-229 cell line, sensitivity to TMZ unexpectedly decreased 
significantly (Figure 39). Likewise, MGMTsil treatment unexpectedly decreased 
sensitivity in the U-87 cell line (Figure 36); but BOTHsil treatment did significantly 
increase TMZ sensitivity. Similarly, the BOTHsil treatment significantly increased TMZ 
sensitivity in the U-138 cell line, but the MGMTsil treatment did not have a significant 
effect (Figure 37). Unlike previous work, MGMTsil was not effective in increasing TMZ 
sensitivity (Davis, 2008). Furthermore, this is not what has been found in the literature 
(Hegi et al., 2005). It is promising that the BOTHsil treatment worked for the U-87 and 
U-138 cell lines to increase TMZ sensitivity, and this type of simultaneous silencing has 
not been reported in the literature. 
Thus, in no instance did MGMTsil treatment contribute to increasing sensitivity to 
TMZ, rather, in two instances it decreased TMZ sensitivity (Figures 36 through 39). 
 
 
These results are not supported by the literature or previous findings (Davis, 2008; Hegi, 
2008). Likewise, in two cell lines, the BOTHsil treatment unexpectedly either decreased 
TMZ sensitivity or had no effect on TMZ sensitivity (Figures 36 and 39). Although this 
isn‟t specifically supported or unsupported by findings in the literature, based on 
functional interactions and single silencing the literature supports the idea that combined 
silencing of MGMT and PARP-1 would increase TMZ sensitivity (Hegi et al., 2005; 
Tentori et al., 2010). However, BOTHsil treatment was able to significantly increase 
TMZ sensitivity in the other two cell lines Figures 37 and 38), both of which had 
previously had insignificant responses to silencing treatments or a decrease in TMZ 
sensitivity. Increased sensitivity to TMZ was the expected response to combination 
silencing; however consider the response to singular silencing it was surprising. 
The other combination treatment, adding a constant dose of the PARP inhibitor 3-
aminobenzamide and constant MGMT silencing to TMZ dose response assays was 
performed in each of the cell lines (Figures 36 through 39). Dose dependent response 
curves to this treatment were characterized in all four cell lines (LN-229, T-98, U-87, and 
U-138) at the 72 hour time point (Figure 35). Accordingly, because the cell lines are from 
four different tumors, it was expected that the curves would be different for each cell line. 
As expected, the 72 hour curves from PARPi+MGMTsil+TMZ treatment showed 
significantly differences between them. Furthermore, the combination treatment of 
PARPi+MGMTsil+TMZ was able to significantly increase TMZ sensitivity in three of 
the four cell lines (Figures 36, 38, and 39). Unexpectedly, in the U-138 cell line, TMZ 
sensitivity was significantly increased (Figure 37). As discussed with the BOTHsil 
groups, there wasn‟t an indication from the literature that any of the cell lines would 
 
 
respond with decreased sensitivity to a treatment targeting MGMT and PARP 
simultaneously (Hegi et al., 2005; Tentori et al., 2010). However, it is encouraging that 
three of the four cell lines, including the cell line most refractory to TMZ treatment in the 
literature and in previous studies (T-98) showed an increased sensitivity to TMZ when 
treated with this combination treatment (Figure 38). Compared to the BOTHsil treatment, 
using the PARP inhibitor with MGMT silencing was more effective in decreasing the 
EC50 of the three cell lines that responded to this treatment. This suggests that some of 
the nonspecific effects of 3-aminobenzamide on PARP-2 could be responsible for 
enhancing TMZ sensitivity in these cell lines (Curtin, 2007; Curtin, 2005).  
 
VARIABLE RESPONSES BY CELL LINE 
 
In the U-87 cell line, the response to silencing treatment was variable (Figure 36). 
The specific targeting of PARP-1 with siRNA did not significantly change the TMZ 
sensitivity, however, when MGMT was targeted, TMZ sensitivity decreased. This finding 
is supported in the literature (Hegi et al., 2005). Because the U-87 cell line had the 
highest PARP-1 gene expression relative to the other cell lines, it is possible that PARPsil 
treatment was unable to decrease PARP-1 expression enough to alter TMZ sensitivity. 
Further studies examining silencing of PARP-1 in the U-87 cells would need to be done 
to validate this claim. It is promising that when both MGMT and PARP-1 were targeted 
with siRNA in the BOTHsil treatment, TMZ sensitivity was significantly increased, 
showing some synergy between these two targets. The most effective treatments in the U-
87 cell line were with the PARP inhibitor alone or in combination with MGMT silencing 
(Figure 36). It is possible that the PARP inhibitor was more effective than PARPsil 
 
 
treatment at modulating the activity of PARP-1 in the U-87 cells, and thus had a larger 
effect. Again, assessing the level of gene expression after silencing and activity of PARP-
1 in these cells would be an appropriate future study. In addition, the PARP inhibitor may 
be having an effect on PARP-2 activity as well (Curtin, 2007). In the combination 
treatment, it is questionable whether the insignificant, however slight, increase in 
sensitivity compared to the PARPi+TMZ treatment is due to the addition of MGMT 
silencing in light of the other MGMT silencing results and because the U-87 cell line has 
low levels of MGMT gene expression (Davis, 2008). Silencing studies looking at the 
expression of MGMT before and after siRNA treatment would shed light on these results. 
The U-138 cell line also had some variable responses to the experimental 
treatments (Figure 37). When PARP-1 and MGMT were silenced alone there was not a 
significant change in TMZ sensitivity; but, when they were silenced in combination, the 
sensitivity to TMZ significantly increased. In light of the expression levels of PARP-1 
relative to the other cell lines, it may not be surprising that PARPsil treatment did not 
have a significant effect; however, it was surprising that this cell line expresses the 
second highest amount of MGMT and did not show a change in sensitivity to TMZ with 
MGMTsil treatment. This is supported by previous work silencing MGMT in the U-138 
cell line (Davis, 2008). However, the significant change in TMZ sensitivity in BOTHsil 
treatment suggests a synergy between PARP-1 and MGMT, where silencing both targets 
is able to increase TMZ sensitivity and this is expected based on the literature (Tentori et 
al., 2008; Tentori et al., 2010). The treatment that most significantly increased sensitivity 
to TMZ in the U-138 cell line was PARPi (Figure 37). In light of the PARPsil treatment, 
it suggests that the more significant effect of the PARPi treatment could be due to some 
 
 
off target effects, such as inhibiting PARP-2, which has related DNA repair functions as 
previously discussed (Tentori and Graziani, 2005). Unexpectedly, the combination 
treatment with inhibition of PARP and MGMT silencing showed a significant decrease in 
TMZ sensitivity. Since this cell line had high MGMT and should have responded to 
MGMTsil treatment, and previously responded positively to PARPi treatment, it is 
possible some alternate form of DNA repair became more favorable, such as HR, which 
would not be inhibited by MGMT or PARP-1 silencing or PARP inhibition. Testing the 
activity of PARP after inhibition with 3-AB in the U-138 cell lines, could shed light on 
these results.  
When the treatments were compared in the T-98 cell line, there were no instances 
where TMZ sensitivity was significantly decreased, as expected (Figure 38). As 
previously discussed, there were no significant differences when MGMT was silenced 
alone or in combination with PARP-1 silencing. Previous work showed that T-98 cells 
had high MGMT expression and they did not show an increase in sensitivity with MGMT 
silencing, however, this may have been due to problems with silencing (Davis, 2008).  
Silencing PARP-1 alone did have a significant effect on TMZ sensitivity, suggesting this 
could be a more important target than MGMT in this cell line. Because this cell line also 
had relatively high levels of PARP-1 expression, it was expected that silencing PARP-1 
would change the response to TMZ, however, this was not supported in the BOTHsil 
treatment. Although PARP inhibition alone and MGMT silencing alone did not produce a 
significant difference in sensitivity, when combined in the PARPi+MGMTsil+TMZ 
treatment, TMZ sensitivity significantly increased (Figure 38). Considering silencing 
MGMT did not previously have an effect on TMZ sensitivity, it is possible that when 
 
 
combined with the PARP inhibitor, with its likely off target PARP-2 inhibitor effects, a 
synergy between the targets occurred to increase TMZ sensitivity (Tentori et al., 2010). It 
is promising that targeting PARP in the T-98 cell line was able to increase sensitivity to 
TMZ, and this may be independent of the high MGMT expression in this cell line. 
The LN-229 cell line had several instances where TMZ sensitivity does not 
appear congruent between treatments (Figure 39). Given that the LN-229 cell line had 
little PARP-1 expression relative to the other cell lines, and virtually undetectable 
MGMT expression, it was unexpected that all of the treatments significantly changed 
TMZ sensitivity (Horton et al., 2009; Liu et al., 2009b). When MGMT was silenced 
alone, or in combination with PARP-1, the cell line became more resistant to TMZ 
treatment, which was unexpected based on the expression of these two proteins in the 
LN-229 cell line and the literature (Liu et al., 2009a; Tentori and Graziani, 2009; Villano 
et al., 2009). Likewise, with PARPi treatment, sensitivity to TMZ decreased, which is not 
supported by the literature, and especially in light of the off target effects of 3-AB it is an 
unexpected result (Goellner et al., 2011). Although MGMTsil treatment was not expected 
to have an effect, considering the lack of MGMT expression, when combined with 
PARPi treatment, which didn‟t have an effect alone, there was a favorable change in 
TMZ sensitivity (Figure 38). Finally, when PARP-1 was silenced alone, there was a 
significant increase in TMZ sensitivity, suggesting that abolishing the small amount of 
PARP-1 in the cell line was able to contribute to TMZ sensitivity. It is likely there are 
several other pathways contributing to the unexpected results in the LN-229 cell line that 
have not been investigated here. 
 
 
Overall, the cell lines had variable responses to the different PARP-1 and MGMT 
treatments and there was not a specific pattern between them. In the U-87 and U-138 cell 
lines, the addition of a PARP inhibitor appears to be the most effective treatment at 
increasing TMZ sensitivity (Figure 36 and 37). For the T-98 and LN-229 cell lines, 
PARP-1 silencing was the most effective treatment (Figure 38 and 39). Although in two 
cell lines (U-87 and U-138) BOTHsil treatment was able to increase TMZ sensitivity, 
silencing either PARP-1 or MGMT alone in those lines was not an effective treatment. In 
contrast, the T-98, LN-229, and U-87 cell lines responded to the combination treatment 
of PARPi+MGMTsil+TMZ with increased sensitivity to TMZ. Finally, only the T-98 cell 
line responded as expected, with no treatment causing a decrease in TMZ sensitivity 
(Goellner et al., 2011; Tentori et al., 2010).  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Comparisons of all five treatments were done to find the most effective method 
for increasing the sensitivity to TMZ in the GBM cell lines (Figures 36 though 39). 
Overall, based on evidence from the literature, there was no indication that any of the 
experimental treatments would decrease TMZ sensitivity in the cell lines. It has been 
previously shown that MGMT silencing should increase TMZ sensitivity (Hegi et al., 
2005; Hegi et al., 2008). This was supported by previous wok silencing MGMT in these 
cell lines (Davis, 2008). Additionally, manipulating  PARP-1 by small molecule 
inhibition or specific silencing was expected to have an effect on TMZ sensitivity 
(Heacock et al., 2010; Mangerich and Burkle, 2011; Maxmen, 2010). In this study, it is 
 
 
likely that the inhibition of PARP-2 by 3-AB contributed to some of the PARPi 
treatments' effects.  
In order to do further analysis of the results presented in this study, the activity of 
PARP-1 after treatment with siRNA and 3-AB should be assessed to determine whether 
the treatments are having the sought after effect inside the cells. Furthermore, it would be 
pertinent to test PARP inhibitors that are more specific for PARP-1 to compare to the 
results from 3-AB, such as some of the PARP inhibitor drugs currently in clinical trials, 
e.g. Olaparib or Iniparib (Curtin, 2007; Mangerich and Burkle, 2011; Olopade et al., 
2008). These studies would help to confirm whether nonspecific effects inhibiting PARP-
2 were affecting changes in sensitivity to TMZ in the cell lines. Finally, a functional 
analysis of the activity of alternate DNA repair mechanisms like HR in these cell lines 
may be able to shed light on why the manipulation of PARP alone was able to increase 
sensitivity more than combined MGMT and PARP manipulation (Bryant et al., 2005; 
Farmer et al., 2005; Tentori et al., 2010; Tucker and Fields, 2003). 
It is promising that the manipulation of PARP was the most effective treatment in all four 
of the cell lines tested. Although there are several studies that would augment these 
studies,  based on results and conclusions presented at this time, manipulating the 
expression or activity of PARP-1 appears to be a worthwhile pursuit for use as an 
adjuvant to TMZ in GBM treatment. Further research using more potent and specific 
PARP inhibitors is underway and should reinforce the data presented herein. 
Additionally, as progress is made in siRNA-based therapies, this will offer a specific 
platform for targeting PARP-1, or other proteins of interest. This may be especially 
important in GBM therapy as wafers releasing PEI-siRNA complexes could be implanted 
 
 
in the cavity during surgery, releasing treatment molecules in to a defined area. 
Moreover, as clinical trials with PARP inhibitors in other cancers continue to give 
promising results, additional studies of PARP inhibitors in glioblastoma will lead the way 
in determining whether this may be a viable treatment option. 
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FIGURES 
 
 
 
 
 
 
 
 
 
Figure 1. mRNA presence verification for GAPDH, PARP-1, and MGMT. Cell lines 
were, from left to right, U-87, U-138, T-98, and LN-229. Genes of interest were GAPDH, 
PARP-1, and MGMT. All cell lines showed bands for each of the genes of interest after 
reverse transcriptase amplification from fresh mRNA samples. 
 
 
 
 
 
U-138 MGMT 24h Silencing
R
e
la
ti
v
e
  
Q
u
a
n
ti
ty
U
nt
re
at
ed
24
h 
M
G
M
T
0.0
0.5
1.0
1.5
**
 
Figure 2. MGMT silencing in U-138 cells at a single time point. Quantitative real-time 
PCR gene expression results for MGMT expression in U-138 cells. Relative quantity 
(RQ) is shown on the Y-axis. Expression was analyzed at 24 hours in untreated U-138 
cells and MGMT siRNA treated cells. MGMT siRNA treated U-138 cells had a 
significantly lower MGMT gene expression level relative to the untreated U-138 cells. 
P=0.0031.  
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Figure 3. MGMT silencing in T-98 cells at three time points. Quantitative real-time 
PCR gene expression results for MGMT expression for silencing in T-98 cells over three 
consecutive time points. Relative quantity (RQ) is shown on the Y-axis. Expression was 
analyzed from mRNA samples extracted from untreated control cells and MGMT siRNA 
treated cells at 24 hours, 48 hours, and 72 hours after silencing. Relative to the MGMT 
gene expression levels in the untreated T-98 cells, all three time points showed 
significantly lower levels of MGMT expression (P=0.0008). In addition, the lower levels 
of expression were carried through the three consecutive time points. A repeated 
measures ANOVA indicated each time point significantly differed from the untreated 
control. The time points did not differ from each other. 
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Figure 4. Baseline expression of PARP-1 in four cell lines. Quantitative real-time PCR 
was used to analyze gene expression of PARP-1 in four cell lines. Relative quantity (RQ) 
is shown on the Y-axis. The cell line with the highest gene expression of PARP-1 was U-
87. The relative to the U-87 cell line, U-138, LN-229, and T-98 cell lines had comparable 
PARP-1 gene expression levels. The level of expression of PARP-1 was significantly 
greater in the U-87 cell line than the other three cell lines (P=0.0001) when analyzed.  
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Figure 5. PARP-1 silencing at a single time point in LN-229 cells. Quantitative real-
time PCR gene expression results for PARP-1 expression comparison in LN-229 cells. 
Relative quantity (RQ) is shown on the Y-axis. Expression of PARP-1 was analyzed at 
24 hours in untreated LN-229 cells (left) and PARP-1 siRNA treated LN-229 cells 
(right). Relative to the untreated LN-229 control, the PARP-1 siRNA treated cells 
showed 65% lower levels of gene expression. 
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Figure 6. PARP-1 silencing at three consecutive time points in T-98 cells. 
Quantitative real-time PCR gene expression results show PARP-1 expression in T-98 
cells. Relative quantity (RQ) is shown on the Y-axis. Analysis was done on mRNA 
extracted from PARP-1 siRNA treated cells at 24 hours, 48 hours, and 72 hours after 
silencing, and an untreated control is shown at the far left. Relative to the untreated T-98 
control sample, the PARP-1 siRNA treated cells showed striking significantly lower 
levels of PARP-1 gene expression (24h, 48h, and 72h samples), (P=0.0003). In addition, 
the level of gene expression appears to decrease over the three consecutive time points, 
however, time points were not significantly different from each other. 
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Figure 7. MGMT expression in U-138 cells after combination silencing. Quantitative 
real-time PCR gene expression analysis showing MGMT expression in U-138 cells at a 
single time point, 24 hours. Untreated control cells (left) show baseline MGMT 
expression. The middle bar represents MGMT expression in U-138 cells after silencing 
with MGMT siRNA. Expression of MGMT after treatment with combined MGMT and 
PARP-1 siRNA is shown on the right. The untreated control U-138 cells showed 
significantly higher levels of gene expression than either of the treated U-138 samples 
(P=0.0002). The levels of gene expression between U-138 cells treated with only MGMT 
siRNA (middle) or both MGMT and PARP-1 siRNAs showed decreased levels of 
MGMT expression compared to untreated, and were not significantly different from each 
other. 
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Figure 8. PARP-1 expression in U-138 cells after combination silencing. Quantitative 
real-time PCR gene expression analysis showing PARP-1 expression in U-138 cells at a 
single time point, 24 hours. Untreated control cells (left) show baseline PARP-1 
expression. The middle bar shows the level of PARP-1 expression in U-138 cells treated 
with PARP-1 siRNA only. On the right, PARP-1 expression in U-138 cells treated with 
combined MGMT and PARP-1 siRNA is shown. Relative to the untreated control, cells 
treated with PARP-1 siRNA or combined PARP-1 and MGMT siRNA showed 
significantly lower levels of PARP-1 gene expression (P=0.0001), but did not differ from 
each other. 
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Figure 9. Dose dependent response to TMZ in four cell lines. Shown above are the 
results from a 24 hour treatment of four cell lines with increasing concentrations of TMZ 
(from untreated to the highest treatment group, 2000 µM). Analysis of the best fit curves 
confirmed there was significant differences between some lines (P<0.0001). 
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Figure 10. TMZ dose response curve at 48 hours. All four cell lines were analyzed at 
48 hours after treatment, shown above.  
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Figure 11. TMZ dose response curve at 72 hours. All four cell lines were analyzed at 
48 hours after treatment, shown above.  
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Figure 12. Time course dose response to TMZ in the U-87 cell line. Dose response 
curves to TMZ were generated at 24, 48, and 72 hours in the U-87 cell line, with 
statistical analysis as previously discussed. The curves show significant differences 
(P<0.0001) and no outliers were found leaving 27 data points. 
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Figure 13. Time course dose response to TMZ in the U-138 cell line. At each time 
point (24, 48, or 72 hours) a dose response curve to TMZ was generated for the U-138 
cell line. The curves were significantly different (P=0.0264) and there were no outliers. 
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Figure 14. Time course dose response to TMZ in the T-98 cell line. Response to TMZ 
was analyzed in the T-98 cell line at three time points: 24, 48, and 72 hours. These curves 
were not significantly different from each other (P=0.2748), and no outliers were 
reported. 
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Figure 15. Time course dose response to TMZ in the LN-229 cell line. Dose response 
curves to TMZ were generated at 24, 48, and 72 hours n the LN-229 cell line as 
previously described. The curves showed differences between them, (P=0.0102), with no 
outliers. 
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Figure 16. Effective concentration of TMZ at 24 hours in four cell lines. The effective 
concentration (EC50) of TMZ at 24 hours in four cell lines. The EC50 values differed 
significantly (P<0.0001). The U-87 median EC50 was 410.6 µM TMZ. The U-138 cell 
line median EC50 was 1135 µM TMZ. The T-98 cell line median EC50 was 1364 µM 
TMZ, and the LN-229 cell line had a median EC50 of 736.9 µM TMZ.  
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Figure 17. Effective concentration of TMZ at 48 hours in four cell lines. EC50 values 
were significantly different from each other (P>0.0001). At 48 hours, the U-87 median 
EC50 increased to 970.0 µM TMZ. The U-138 cell line median EC50 decreased at 48 
hours to 860.0 µM TMZ. The T-98 cell line median EC50 was 1305 µM TMZ, the LN-
229 cell line had a median EC50 of 543.7 µM TMZ. 
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Figure 18. Effective concentration of TMZ at 72 hours in four cell lines. TMZ EC50 
values of the four cell lines at 72 hours showed that they were not significantly different 
when compared (P=0.0659). The median EC50 values for all four cell lines were: 859.5 
µM TMZ (U-87), 696.0 µM TMZ (U-138), 1048.0 µM TMZ (T-98), and 811.9 µM TMZ 
(LN-229).  
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Figure 19. U-87 temozolomide EC50 over three time points. The U-87 cell line had 
EC50 values that were significantly different from each other when analyzed (P=0.0012). 
The EC50 at 24 hours was highly significantly different than the 48 and 72 hour values. 
The 48 and 72 hour values were not significantly different from one another. 
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Figure 20. U-138 temozolomide EC50 over three time points. An ANOVA showed the 
U-138 EC50 values were significantly different (P<0.0001). All time points differed. 
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Figure 21. T-98 temozolomide EC50 over three time points. The T-98 cell line EC50 
values were analyzed and were not significantly different (P=0.3262). 
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Figure 22. LN-229 temozolomide EC50 over three time points. EC50 values for the LN-
229 cell line were significantly different (P=0.0053). The 24 hour values were highly 
significantly different from the 48 hour EC50, and the 48 hour value also highly 
significantly different than the 72 hour EC50. The 24 hour value was not significantly 
different than the 72 hour value.  
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Figure 23. Dose response curves for four cell lines treated with TMZ and the PARP 
inhibitor 3-aminobenzamide. Shown are the results of a TMZ dose response curve at 72 
hours with the addition of a constant concentration of PARPi (33 µM 3-AB). Analysis 
confirms differences in the best fit curves (P<0.0001) with the exclusion of a single 
outlier from the T-98 cell line (extra T-98 data point in dark green).  
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Figure 24. Dose response curves for four cell lines silenced for PARP-1 and treated 
with TMZ. Shown are the results of a 72 hour TMZ dose response curve with constant 
PARP-1 silencing. Curve analysis confirms the curves are significantly different from 
one another (P<0.0001) with the exclusion of six outliers (four in LN-229, shown in dark 
red, and two in T-98, shown in dark green).  
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Figure 25. U-87 dose response curve comparison for three treatments: TMZ only, 
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for 
each group. The best fit curves showed significant differences (P=0.0189) when 
analyzed. Inhibition of PARP (PARPi) and silencing of PARP (PARPsil) were constant 
and dose dependent response was only assessed for TMZ. No outliers were found in this 
analysis. 
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Figure 26. EC50 comparison for U-87 cells treated with TMZ only, TMZ + PARPi, 
or TMZ + PARPsil. There were significant differences between groups (P=0.0012). The 
TMZ only treatment (median EC50 of 859.5 µM TMZ) showed a highly significant 
difference from the TMZ + PARPi treatment (median EC50 of 604.2 µM TMZ). The 
TMZ only treatment was not significantly different than the TMZ + PARPsil (median 
EC50 of 849.1 µM TMZ). The two PARP treatments, TMZ + PARPi and PARPsil were 
highly significantly different from each other. 
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Figure 27. U-138 dose response curve comparison for three treatments: TMZ only, 
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for 
each group. The curves were significantly different from one another (P=0.0487). 
Inhibition of PARP (PARPi) and silencing PARP (PARPsil) were done at the same level 
constant and dose dependent response was only assessed for TMZ. No outliers were 
found. 
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Figure 28. EC50 comparison for U-138 cells treated with TMZ only, TMZ + PARPi, 
or TMZ + PARPsil. ANOVA analysis showed significance (P=0.0006). The TMZ only 
treatment (median EC50 of 696.0 µM TMZ) showed a very highly significant difference 
from the TMZ + PARPi treatment (median EC50 of 502.1 µM TMZ). The TMZ only 
treatment was not significantly different than the TMZ + PARPsil (median EC50 of 655.5 
µM TMZ). The two PARP treatments, TMZ + PARPi and PARPsil were highly 
significantly different from each other. 
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Figure 29. T-98 dose response curve comparison for three treatments: TMZ only, 
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for 
each group. The curves were significantly different (P<0.0001) from one another. 
Inhibition of PARP (PARPi) and silencing PARP (PARPsil) were constant and dose 
dependent response was only assessed for TMZ. Two outliers were reported in the 
PARPsil treatment group (dark green), and excluded from analysis. 
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Figure 30. EC50 comparison for T-98 cells treated with TMZ only, TMZ + PARPi, 
or TMZ + PARPsil. ANOVA analysis showed significance (P=0.0381). The TMZ only 
treatment (median EC50 of 1048.0 µM TMZ) did not show a significant difference from 
the TMZ + PARPi treatment (median EC50 of 771.3 µM TMZ). The TMZ only treatment 
was significantly different than the TMZ + PARPsil (median EC50 of 423.2 µM TMZ). 
The two PARP treatments, TMZ + PARPi and PARPsil were not significantly different 
from each other. 
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Figure 31. LN-229 dose response curve comparison for three treatments: TMZ only, 
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for 
each group. The curves were not significantly different from one another. Inhibition of 
PARP (PARPi) and silencing PARP (PARPsil) were constant and dose dependent 
response was only assessed for TMZ. There were three outliers found in this analysis in 
the PARPsil treatment group, indicated in dark red.  
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Figure 32. EC50 comparison for LN-229 cells treated with TMZ only, TMZ + 
PARPi, or TMZ + PARPsil. ANOVA performed on the extrapolated EC50 values 
showed significance (P=0.0003). The TMZ only treatment (median EC50 of 811.9 µM 
TMZ) showed a highly significant difference from the TMZ + PARPi treatment (median 
EC50 of 1179.0 µM TMZ). Additionally, the TMZ only treatment was highly significantly 
different than the TMZ + PARPsil (median EC50 of 453.2 µM TMZ). Finally, the two 
different PARP treatments, TMZ + PARPi and PARPsil were also very highly 
significantly different from each other. 
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Figure 33. Dose response curves for four cell lines silenced for MGMT and treated 
with TMZ. Shown are the results at 72 hours of constant silencing of MGMT 
(MGMTsil) with dose response curve of TMZ. The curves were significantly different 
from one another (P=0.0005). No outliers were found during the analysis.  
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Figure 34. Dose response curves for four cell lines silenced for MGMT and PARP-1 
and treated with TMZ. Shown are the results from a 72 hour dose response curve of 
TMZ in cell double silenced for MGMT and PARP-1 (BOTHsil). The curves were 
significantly different from one another (P<0.0001). One outlier (U-138 cell line) was 
excluded. 
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Figure 35. TMZ dose response curve for four cell lines with constant MGMT 
silencing and PARPi treatment. Shown are the results from a 72 hour TMZ dose 
response curve where MGMT was silenced in cells and PARP was inhibited with a 
constant 33 µM dose of 3-aminobenzamide. Surprisingly, the curves are significantly 
different from one another and no outliers were found (P=0.0051).  
 
 
 
U-87  TMZ EC50  Treatment  Comparison
T
M
Z
( 
M
)
TM
Z 
O
nl
y
P
A
R
P
i +
 T
M
Z
P
A
R
P
si
l +
TM
Z
M
G
M
T 
si
l +
 T
M
Z
B
O
TH
 s
il 
+ 
TM
Z
P
A
R
P
i +
M
G
M
T 
si
l +
 T
M
Z
0
500
1000
1500
***
***
***
**
 
Figure 36. Treatment comparisons of EC50 values in the U-87 cell line. Shown are the 
EC50 values from 72 hours treatments of the following (from left to right): TMZ only, the 
addition of a constant dose of 33 µM 3-aminobenzamide to TMZ (PARPi+TMZ), 
addition of constant silencing of PARP-1 to TMZ treatment (PARPsil+TMZ), addition of 
constant MGMT silencing to TMZ treatment (MGMTsil+TMZ), addition of silencing 
both PARP-1 and MGMT to TMZ treatment (BOTHsil+TMZ), and finally, addition of 
PARP inhibition and MGMT silencing to TMZ treatment (PARPi+MGMTsil+TMZ). 
The treatment groups were significantly different from each other according to ANOVA 
analysis, (P<0.0001). Median EC50 values for each treatment from left to right are as 
follows: 859.5, 604.2, 849.1, 1027.0, 739.4, and 599.2 (in µM TMZ concentrations). 
Compared to the TMZ only control, the PARPi+TMZ treatment showed a very highly 
significant EC50 decrease, however the PARPsil+TMZ treatment was not significantly 
different. The MGMTsil+TMZ treatment showed a very highly significant EC50 increase 
compared to the TMZ only control. When both PARP-1 and MGMT were (BOTHsil) 
with TMZ treatment, the EC50 was highly significantly decreased compared to the TMZ 
only treatment. When treated with PARPi+MGMTsil+TMZ, there was a very highly 
significant EC50 decrease compared to the TMZ control. 
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Figure 37. Treatment comparisons of EC50 values in the U-138 cell line. Shown are 
the EC50 values from 72 hours treatments. The treatments are the same as previously 
described, and were significantly different (P<0.0001). Median EC50 values for the 
treatments from left to right were: 696.0, 502.1, 655.5, 638.2, 546.5, and 901.5 (in µM 
TMZ). Compared to the TMZ only control, the addition of a PARP inhibitor highly 
significantly decreased the EC50. The single silencing, PARPsil and MGMTsil, were not 
significantly different than the TMZ only control. When both PARP-1 and MGMT were 
silenced together (BOTHsil), the EC50 was significantly different than the TMZ only 
treatment. When MGMT was silenced with PARPi in addition to TMZ treatment, the 
EC50 highly significantly increased compared to the TMZ only control. 
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Figure 38. Treatment comparisons of EC50 values in the T-98 cell line. Shown are the 
EC50 values from 72 hours treatments. The treatments, as previously described, were 
significantly different (P=0.0040). From left to right, the median EC50 values were: 
1048.0, 771.3, 423.2, 958.3, 771.8, and 556.6 (in µM TMZ concentrations). Compared to 
the TMZ only control, the PARPsil and the PARPi+MGMTsil treatments showed 
significantly decreases in the EC50 values. The other three treatments were not 
significantly different than the TMZ only control. In addition, the PARPsil treatment was 
significantly different than the MGMTsil treatment when compared. 
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Figure 39. Treatment comparisons of EC50 values in the LN-229 cell line. Shown are 
the EC50 values from 72 hours treatments. Treatments are as previously described, and 
were significantly different from each other (P<0.0001). From the TMZ only control to 
the PARPi+MGMTsil+TMZ treatment, median EC50 values were: 811.9, 1179.0, 453.2, 
1022.0, 1139.0, and 574.1 (in µM TMZ). Compared to the TMZ only control, the 
PARPi+TMZ treatment showed a very highly significant increase in EC50, similar to the 
highly significant increases in the EC50 values for the MGMTsil treatment and very 
highly significant BOTHsil treatment, when compared to the TMZ only treatment. A very 
highly significant decrease in EC50 compared to the TMZ only treatment was observed 
in the PARPsil treatment and the PARPi+MGMTsil treatment. 
 
  
 
 
 
